Vista Partners LLC | Biotech & HealthcareVista Partners LLC

Johnson’s Covid Vaccine Under Review By EU Regulator After Blood Clots Reports Surface

As per reports, Johnson & Johnson’s (JNJ) Covid-19 vaccine is under review by the European Union’s drug regulator after four critical cases of unusual clots accompanied by low blood platelets were reported after taking the immunization with the J&J shot. The regulator is now investigatin...

Apr 12, 2021 View Article

UnitedHealth Group Appoints Brian Thompson As CEO For Its UnitedHealthcare Unit

Brian Thompson has been named as the Chief Executive Officer of UnitedHealthcare, the health benefit unit of UnitedHealth Group (UNH), as per reports. Thompson joined UnitedHealth Group in 2004 and recently served as CEO of UnitedHealthcare's government programs including the Medicare & Retireme...

Apr 09, 2021 View Article

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical t...

Apr 08, 2021 View Article

Walgreens-Backed Primary Healthcare Provider, VillageMD Prepares For IPO

As per reports, VillageMD, backed by Walgreen Boots Alliance (WBA) is preparing to go public in the U.S. in an IPO. Founded in 2013, VillageMD, a primary healthcare provider plans to raise more than $500 million in a listing that is expected to happen in the third quarter. The IPO could raise as muc...

Apr 08, 2021 View Article

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the full year ended December 31, 2020. “We are executi...

Apr 07, 2021 View Article

Merck Acquires Pandion Therapeutics

As per reports, Merck & Co., Inc. (MRK) has completed the acquisition of Pandion Therapeutics, Inc, for all of the outstanding shares of the common stock of Pandion Therapeutics, Inc at $60 per share through a subsidiary after successful completion of the cash tender offer. Pandion is set to bec...

Apr 07, 2021 View Article

Johnson & Johnson Now In-Charge Of COVID-19 Vaccine Production At Baltimore Plant After 15 Million Doses Spoil

Reportedly, The U.S. Department of Health and Human Services has put Johnson & Johnson (JNJ) in charge of the Emergent BioSolutions facility in Baltimore that ruined 15 million doses of its COVID-19 vaccine. The incident has stopped British drugmaker AstraZeneca Plc from using the facility and w...

Apr 07, 2021 View Article

3M Launches New Silicone Adhesive

Reportedly, 3M (MMM) announced its latest addition to a new class of silicone adhesives that balances strength, flexibility, and comfort, the 2484 3M™ Single Coated Medical Film Tape with Hi-Tack Silicone Adhesive on Liner. The adhesive is breathable, comfortable, and enables up to a seven-day wea...

Apr 07, 2021 View Article

Amgen Announces Acquisition Of Rodeo Therapeutics Corporation

As per reports, Amgen Inc. (AMGN) has reached an agreement to acquire Rodeo Therapeutics Corporation, a Seattle-based privately-held biopharmaceutical company that develops small-molecule therapies focused to promote the repair and regeneration of multiple tissues. As per the terms of the deal, Amg...

Apr 07, 2021 View Article

INVO Bioscience, Inc. (Nasdaq: INVO) Reports Yearend Financial Highlights & Recent Operational Highlights Financial Highlights

On March 30, 2021 INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, announced its financial results for the year e...

Mar 31, 2021 View Article

Chinook Therapeutics’ Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

Chinook Therapeutics, Inc. (NASDAQ: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chino...

Mar 31, 2021 View Article

Atossa Therapeutics (ATOS) Financial Results & Key Developments For The Fiscal Year Ended December 31, 2020

Today, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced financial results for the fiscal year ended ...

Mar 31, 2021 View Article

Merck’s Spinoff Unit Organon To Acquire Alydia Health – Medical Device Co. Focused on Preventing Maternal Mortality

As per reports, Merck & Co., Inc.(MRK) Inc. has entered into a definitive agreement with Alydia Health, following the spinoff of its women’s health under the new company, Organon. Organon, a global healthcare company will acquire Alydia Health, focusing on improving the overall health of women...

Mar 31, 2021 View Article

Walgreens Beats Q2 Estimates – Raises 2021 Profit Forecast

As per reports, Walgreen Boots Alliance (WBA) reported its second-quarter earnings this week beating estimates and reporting an 8.4% rise in quarterly profit due to higher sales at its pharmacy stores in the U.S. and the UK. The retailer reported a 4.5% increase in its same-store sales at its U.S. ...

Mar 31, 2021 View Article

VISTA ALERT: INVO Bioscience (NASDAQ: INVO) Releasing Results After Market Close Today! – Conference Call 4:30pm ET

INVO Bioscience, Inc.(NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its fourth quarter and fis...

Mar 30, 2021 View Article

Immune Monitoring Technology Firm Aditxt Prepares Therapeutic Program For Psoriasis For First-In-Human Clinical Trials

Mountain View, California-based Aditx Therapeutics (NASDAQ: ADTX) is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The Company's immune monitoring technology is designed to provide a personalized comprehensive ...

Mar 29, 2021 View Article

INVIMA Confirms Johnson & Johnson’s One Shot Covid-19 Vaccine Shot Receives Approval For Emergency Use In Columbia

Reportedly, Colombia has approved the emergency use of Johnson & Johnson's (JNJ) one-shot COVID-19 vaccine, informed the director of food and drug regulator INVIMA. The government has entered an agreement to buy 9 million doses of J&J's one-shot vaccine. "In its capacity as regulator, INV...

Mar 26, 2021 View Article

Rebecca Herron, A Woodway Woman, Inspires Others With Her Breast Cancer Journey Through Photo Shoot

Rebecca Herron of Woodway, 52, shares her journey of her battle with breast cancer seeking to inspire many to stay strong and positive. After two months of diagnosis, Herron started her fight with the potentially deadly disease through chemotherapy. She chose to portray her journey with a series of ...

Mar 25, 2021 View Article

UnitedHealth Group Announces Q1 Earnings Release Date

Reportedly, the UnitedHealth Group (UNH) will announce its first-quarter 2021 financial results on Thursday, April 15, 2021, before the stock market opens. The company to host a teleconference at 8:45 a.m. ET to discuss and review the results with analysts and investors. The call will be available...

Mar 24, 2021 View Article

Atossa Therapeutics Adds $50M Via Registered Direct Offering On Monday!

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. On March 11, 2021 announced the FDA has issued a “Saf...

Mar 22, 2021 View Article

EMA Issues Warnings Against The Use Of Merck’s Anti-Parasite Drug For COVID-19

As per reports, the European Medicines Agency has issued warnings against the use of ivermectin, Merck & Co's (MRK) anti-parasite drug for the prevention or treatment of COVID-19 outside clinical trials. A similar warning was also issued from the U.S. Food and Drugs Administration stating, as p...

Mar 22, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Approved For Use In Switzerland

Reportedly, Swiss drug regulator Swissmedic has approved Johnson & Johnson's (JNJ) COVID-19 vaccine for usage in the country, following the earlier two approved vaccines from Pfizer and BioNTech and from Moderna. Switzerland has so far not ordered J&J's one-shot vaccine, while deliveries hav...

Mar 22, 2021 View Article

Johnson & Johnson’s Multiple Sclerosis Treatment Drug Secures FDA Approval – Launching April 2021

Reportedly, FDA has approved Johnson & Johnson’s (JNJ) Ponvory, as a daily oral drug to treat relapsing forms of multiple sclerosis MS. The drug is expected to launch in early April 2021, entering a market currently dominated by big names like Novartis’ Kesimpta, Roche’s Ocrevus, and Gilen...

Mar 22, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Gains Approval From Italy’s Medicines Agency For Usage

Reportedly, AIFA, Italy's medicines agency has approved the use of the single-dose COVID-19 vaccine produced by Johnson & Johnson following approval from the European drugs regulator last week. The J&J's vaccine approval marks fourth to be allowed for use in the European Union after vaccines...

Mar 16, 2021 View Article

PROGRESS REPORT: INVO Biosciences Signs JV Agreement To Open 1st U.S. INVOcell-Exclusive Clinic

The infertility population in the U.S. is large and significantly underserved. Currently, it is estimated that more than 90% of the patients who need advanced fertility treatment are unable access it. - Dr. Karen Hammond INVO Bioscience, Inc. (NASDAQ: INVO) is a medical device company focused on...

Mar 16, 2021 View Article

Merck Stocks Rise As Its Oral Antiviral Treatment Shows Promising Results

Reportedly, Merck & Co., Inc. (MRK) stocks soared after its Ridgeback Biotherapeutics-partnered Covid-19 treatment known as molnupiravir displayed promising results in an interim analysis of a Phase 2. Merck stock recently slipped this year after the company scrapped the development of two "i...

Mar 10, 2021 View Article

PROGRESS REPORT: INVO Bioscience & Ferring Pharma Agree For Increase Of INVO Company-Owned U.S. Clinics

INVO Bioscience, Inc.'s (NASDAQ: INVO) INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and In...

Mar 08, 2021 View Article

Amgen Buys Five Prime Deal For $1.9B Boosting Its Cancer Pipeline

As per reports, Amgen Inc. (AMGN) will buy Five Prime Therapeutics Inc. for $1.9 billion in cash that will add new cancer therapies to the pharmaceutical giant’s pipeline. Amgen will pay $38 a share for Five Prime, the transaction is expected to close by the end of the second quarter. South San F...

Mar 08, 2021 View Article

AstraZeneca-Amgen Asthma Drug Shows Promising Results

Reportedly, Amgen's (AMGN) and AstraZeneca's (AZN) experimental drugs have proven to reduce asthma attacks in patients with uncontrolled and severe forms of the respiratory condition in a large study. The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to p...

Mar 04, 2021 View Article

iPSC-Derived Cell Therapy Firm, Century Scores Casdin Capital Led $160M Series C Financing

Philadephia-based Century Therapeutics reports to be harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Their genetically engineered, iPSC-derived iNK and iT cell products are said to be desi...

Mar 03, 2021 View Article

Walgreens Boots Alliance To Release Fiscal 2021 Q2 Earnings On March 31, 2021

As per reports, Walgreens Boots Alliance, Inc. will announce its fiscal 2021 second-quarter earnings results on Wednesday, March 31, 2021, at 7 a.m. Eastern time. The release will be followed by a one-hour conference call with the management beginning at 8:30 a.m. Eastern time. The conference call c...

Mar 03, 2021 View Article

Merck To Assist In Production Of J&J’s Single-Dose COVID-19 Vaccine, Snags Funds From BARDA To Expand Facilities

Reportedly, Merck & Co., Inc. (MRK) has entered into multiple agreements to expand and support the manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. BARDA, the Biomedical Advanced Research and Development Authority, a unit of the Office of the Assistant Secret...

Mar 03, 2021 View Article

TRIBE INVITATION: “Advancing A Unique Broad-based Vaccine Approach To Fighting COVID-19, Ebola & Beyond!”

You are cordially invited to join me at our sister organization's Tribe Public Webinar Presentation and Q&A Event which will be held today, Wednesday, March 3 (8:30 am PT/ 11:30 am ET). Tribe Public's (www.tribepublic.com) complimentary worldwide webinars are efficient 30-minute events that seek...

Mar 03, 2021 View Article

Mexico’s COFEPRIS Approves The Importation of INVO Bioscience’s INVOcell, An Effective & Affordable Alternative To IVF

COFEPRIS or the Federal Committee for Protection from Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios) is the department within the Mexican Secretariat of Health that deals with the importation of medical devices and issues advertising permits for...

Mar 02, 2021 View Article

NKCell Firm Cytovia Therapeutics Announced The Opening of New Boston R&D Center of Excellence & cGMP Manufacturing Facility

Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical r...

Mar 02, 2021 View Article

VP WATCHLIST PROGRESS REPORT: Chinook Therapeutics (KDNY), INVO Bioscience (INVO), PLUG Power (PLUG)

The VP Watchlist currently contains 10 coverage companies that we believe deserve consideration for short term and long term portfolio additions. Here are today's updates on 3 of the companies from the list. Chinook Therapeutics, Inc. (NASDAQ: KDNY) ($17.23, +4.17%) and Evotec SE today announc...

Mar 01, 2021 View Article

FDA Approves Johnson & Johnson Single-Dose Covid-19 Vaccine Shot For Use In The U.S

As per reports, the Food & Drug Administration has given clearance to Johnson & Johnson (JNJ) Covid-19 one-shot vaccine giving the U.S its third vaccine to prevent the pandemic. Health officials have been waiting for a one-dose option instead of two to help fasten the vaccination drive, as t...

Mar 01, 2021 View Article

PROGRESS REPORT: Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Today, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19, announced final results...

Feb 25, 2021 View Article

UnitedHealth Group Board Announces Cash Dividend, Payable On March 23

As per reports, the board of the UnitedHealth Group (UNH) has announced a cash dividend of $1.25 per share to all common stock shareholders as of March 15, 2021. The dividend is to be paid on March 23, 2021. Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and...

Feb 25, 2021 View Article

NK Cell Firm Fate Therapeutics Reports Q4 & Full Year Results While Confirming ‘2020 Was A Pivotal Year’

San Diego-based Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal...

Feb 24, 2021 View Article

Johnson & Johnson Submits Covid-19 Vaccine Data To World Health Organization For Emergency Use Listing

As per reports, Johnson & Johnson (JNJ) has submitted data to the World Health Organization (WHO) for emergency use listing of its single-dose COVID-19 vaccine, allowing wider access. The healthcare giant informed that an emergency use listing is mandatory for supplying vaccines to the COVAX va...

Feb 23, 2021 View Article

San Diego-Based Fate Therapeutics To Host Q4/Full Year 2020 Earnings & Corporate Update Conference Call Wednesday, February 24, 2021

San Diego-based Fate Therapeutics, Inc. (NASDAQ: FATE) has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product can...

Feb 19, 2021 View Article

Iowa Withdraws From Microsoft’s COVID-19 Vaccine Scheduling Software Deal

As per reports, Iowa is backing out of a plan to use Microsoft Corp. (MSFT) software for registering and scheduling patients for the Covid-19 vaccinations. Iowa Governor Kim Reynolds announced the news at a conference, this week. He said state officials concluded it would be too hard to combine exis...

Feb 18, 2021 View Article

TALEN® Gene-Edited iPSC-Derived Natural Killer Cells To Be Developed By Cytovia Therapeutics & Cellectis (NASDAQ: CLLS) Partnership

Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical r...

Feb 16, 2021 View Article

PROGRESS REPORT: NeuBase Therapeutics (NBSE) Reports Financial Results for Q1 Fiscal Year 2021

Pittsburgh-based NeuBase Therapeutics (NASDAQ: NBSE) is a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living sy...

Feb 12, 2021 View Article

A Letter From Atossa Therapeutics (NASDAQ: ATOS) President and CEO Dr. Steven C. Quay M.D., Ph.D.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19. Atossa Therapeutics (NASDAQ: ATOS) P...

Feb 10, 2021 View Article

Amgen Releases Q4 Earnings – Lowers 2021 Outlook Below Estimates

U.S. biotech, Amgen (AMGN) announced a higher-than-expected profit for the fourth quarter reporting adjusted earnings per share of $3.81 beating the analyst estimate by 41 cents. Net profit for the quarter dropped 3% to $2.76 per share. Revenue increased 7% to $6.6 billion. Sales of rheumatoid arthr...

Feb 08, 2021 View Article

UnitedHealthcare Enters The Oklahoma Medicaid Market With SoonerSelect

Reportedly, the Oklahoma Health Care Authority has selected the UnitedHealthcare (UNH) Community Plan of Oklahoma to administer SoonerSelect, its statewide Medicaid program starting later this year. UnitedHealthcare will work with the state offering self-management care solutions and improving the ...

Feb 08, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Awaits FDA Authorization

Reportedly, Johnson & Johnson (JNJ) has submitted its single-shot coronavirus vaccine for emergency use with the Food and Drug Administration for authorization. If authorized, the company plans to supply the U.S. with 100 million doses in the first half of 2021, also it expects to begin shipment...

Feb 07, 2021 View Article

FDA Grants Rare Pediatric Disease Designation to Precision Medicine Firm Chinook Therapeutics’ CHK-336 For Primary Hyperoxaluria (PH)

Hyperoxalurias, including PH, are diseases caused by excess oxalate, a potentially toxic metabolite typically filtered by the kidneys and excreted as a waste product in urine. Symptoms of PH include recurrent kidney stones, severe pain, blood in the urine and urinary tract infections; which when...

Feb 04, 2021 View Article

Salesforce To Launch Vaccine Cloud To Assist COVID-19 Vaccination Drive

As per reports, Salesforce Inc. (CRM) will launch Vaccine Cloud to assist healthcare providers and the government to globally record, manage, maintain records of COVID-19 vaccinations digitally. The vaccine Cloud will assist people to register and schedule for their vaccine shots, share their vaccin...

Feb 04, 2021 View Article

Breast Cancer & COVID-19 Focused Atossa Therapeutics Receives Another $21M & Presenting Feb.2 At Tribe Public

Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has received $21 million from the exercise of outs...

Jan 29, 2021 View Article

NeuBase Therapeutics’ Acquisition Of Gene Modulating Technology Believed To Extend Ability Of Existing Tech Platform To Directly Modulate The Human Genome

Today, Pittsburgh-based NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines to drug the genome, announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for...

Jan 28, 2021 View Article

Highlights From Johnson & Johnson’s Q4 Earnings Release

Johnson & Johnson (JNJ) reported their Q4 earnings and revenue numbers which exceeded market estimates, reporting EPS of $1.86 per share versus $1.82 expected and revenue of $22.48 billion versus $21.67 billion expected. The company’s pharmaceutical unit, also working on a coronavirus vacci...

Jan 27, 2021 View Article

3M Beats Q4 Estimates On Shoulders of Health-Care Division During The Covid-19 Pandemic

3M (MMM) reported better than expected Q4 earnings recently, driven by an increase in demand for its healthcare products during the Covid-19 pandemic. The company’s health-care unit recorded 12.3% in 2020 due to high consistent demand for its disposable respirators and safety products such as hand...

Jan 26, 2021 View Article

Atossa Therapeutics CEO Dr. Steven C. Quay & Anthony S. Fauci, MD, Director NIAID to Speak at Precision Medicine World Conference January 25-27, 2021 – “Development of New SARS-CoV-2 Therapeutics”

Seattle-based Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that Dr. Steven C. Quay, MD., Ph.D., P...

Jan 25, 2021 View Article

UnitedHealth Reports High Profits, Exceeds Expectations On Lower Medical Costs Amid Covid-19 Pandemic

UnitedHealth Group Incorporated (UNH) released better than expected quarterly earnings this week, reporting adjusted earnings of $2.52 per share while beating Wall Street estimates by 11 cents, as per reports. Health insurers incurred lower healthcare costs, for much of 2020 as people avoided docto...

Jan 25, 2021 View Article

You Are Cordially Invited To Tribe Public’s FREE Webinar Event “ALIGNed in the Fight Against Kidney Diseases” -Tuesday, January 26th (Meet Eric Dobmeier, CEO of Chinook Therapeutics (KDNY)

You are cordially invited to attend the next Tribe Public FREE Webinar Presentation and Q&A Event titled "ALIGNed in the Fight Against Kidney Diseases." The event will be co-hosted by yours truly, John F. Heerdink, Jr., managing member fo Tribe Public and Vista Partners and Eric Dobmeier, Pre...

Jan 25, 2021 View Article

INVO Bioscience Seeks To Expand Access To Infertility Care With INVOcell In The Fifth Most Populous Country In The World, Pakistan, With ~212 million People

Sarasota-based INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, recently announced it has entered an exclu...

Jan 23, 2021 View Article

Microsoft, Oracle, Cigna, Mayo Clinic , etc. Forming Coalition To Digitally Track Covid-19 Vaccinations

Reportedly, Tech giants Microsoft Corp (MSFT) & Oracle Corp, and healthcare companies Cigna Corp and the Mayo Clinic are part of an alliance working to help people get encrypted digital copies of their immunization records stored in a digital wallet of their choice under the project called Vacci...

Jan 17, 2021 View Article

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors

Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical r...

Jan 14, 2021 View Article

Amgen Announces Seven-Year Environmental Sustainability Plan

As per reports, Amgen (AMGN) has announced its new seven-year environmental sustainability plan 2027 with a commitment to achieve carbon neutrality along with a reduction in water use by 40% and waste disposal by 75%. Since 2007, Amgen has achieved a 33% reduction in carbon emissions, a 30% reducti...

Jan 13, 2021 View Article

Disneyland Creating A Super Point-Of-Dispensing (POD) For Mass COVID-19 Vaccination In Orange County

Reportedly, Walt Disney Co's (DIS) Disneyland which has been closed since March 2020 will become the first largest Super Point-of-Dispensing (POD) sites to provide COVID-19 vaccinations in Orange County, California. The facility is expected to host the operations later this week, informed government...

Jan 12, 2021 View Article

Walgreens Tops Earning Estimates, Assisted By Strong Pharmacy Sales

Walgreen Boots Alliance (WBA) reported its fiscal Q1 earnings, beating Wall Street estimates driven by strong pharmacy sales. Earning highlights for the first quarter ending November, 30: Adjusted EPS of $1.22 cents per share was reported, versus $1.03 expected. Revenue of $36.31 billion was ...

Jan 09, 2021 View Article

Johnson & Johnson Announces Q1 2021 Dividend Date

Reportedly, the Board of Johnson & Johnson (JNJ) has declared a cash dividend of $1.01 per share payable on March 9, 2021, to shareholders of common stock and of record at the close of business on February 23, 2021. Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused ...

Jan 08, 2021 View Article

Key Developments & Future Initiatives Position INVOcell® Within the Severely Underserved Fertility Market

Good morning! I hope that all of you are having a great start to your day here in the states or if I am reaching you across the world then hopefully your evening is treating you well too. I wanted to make sure that you were aware that INVO Bioscience, Inc. (NASDAQ: INVO) ($2.99/share, $28.59M ...

Jan 08, 2021 View Article

Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS) , a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securitie...

Jan 07, 2021 View Article

United Health’s OptumInsight & Change Healthcare Joining Forces To Implement Modern Information & Technology-Enabled Health Care Platform

Reportedly, Optum, a diversified health services company and part of UnitedHealth Group (UNH), and Change Healthcare, a health care technology leader have agreed to come together to improve and upgrade healthcare services for everyone. Change Healthcare will join with OptumInsight to provide technol...

Jan 07, 2021 View Article

AmerisourceBergen Corp Agrees To Purchase Walgreens Boots Alliance Inc.’s Pharmaceutical Business

Reportedly, AmerisourceBergen Corp. (ABC) will purchase Walgreens Boots Alliance Inc.’s (WBA) pharmaceutical wholesale businesses for about $6.5 billion in cash and stock, extending its reach in Europe. The deal includes $6.275 billion in cash and 2 million in shares. Walgreens and AmerisourceBerg...

Jan 06, 2021 View Article

Columbia Enters Deal With Janssen For 9M COVID-19 Vaccine Doses

As per reports, Columbia has signed an agreement with Janssen, Johnson & Johnson's (JNJ) pharmaceutical division to acquire 9 million doses of coronavirus vaccines. Columbia with over 1.6 million cases of coronavirus and 43,000 deaths, had earlier secured deals with Pfizer and AstraZeneca Plc t...

Dec 31, 2020 View Article

AstraZeneca & Merck LYNPARZA®Receives Three New Advanced Cancer Approvals In Japan

As per reports, AstraZeneca and Merck’s (MRK) LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate, and pancreatic cancer. The approvals authorize LYNPARZA for use as maintenance treatment after first-line chemotherapy for the above cancers. Th...

Dec 31, 2020 View Article

Amgen’s Sotorasib Submitted For Marketing Authorization Application In Europe

Reportedly, Amgen has submitted Marketing Authorization Application to the European Medicines Agency (EMA) for sotorasib, an investigational KRASG12C inhibitor for patients previously treated non-small-cell lung cancer (NSCLC) with the KRAS G12C Mutation. The submission is backed by positive Phase ...

Dec 28, 2020 View Article

Merck Enters Supply Agreement With U.S. Government For Investigational Biological Therapeutic, MK-7110 For Severe & Critical COVID-19

Reportedly, Merck & Co., Inc. (MRK) has entered an agreement with the United States Government development, manufacture, and initial distribution of an investigational biological therapeutic, MK-7110 upon approval or Emergency Use Authorization from the U.S. Food and Drug Administration (FDA)....

Dec 25, 2020 View Article

Honeywell Dives Deeper Into Life Sciences Expansion With $1.3B Acquisition Of Sparta Systems

As per reports, Honeywell to acquire privately-held Sparta Systems, a leading provider of enterprise quality management software including a next-generation SaaS platform for the life sciences industry for $1.3 billion in an all-cash transaction from New Mountain Capital. The acquisition will streng...

Dec 23, 2020 View Article

Walgreens To Administer Pfizer’s COVID-19 Vaccine In Long-Term Care Facilities

Reportedly, Walgreen Boots Alliance (WBA) plans to administer Pfizer’s COVID-19 vaccine to approximately 3 million residents and staff in 35,000 long-term care facilities as part of the Centers for Disease Control and Prevention Program for long-term care program. The pharmacists are providing the...

Dec 19, 2020 View Article

AstraZeneca Agrees To Buy Rare Disease Firm Alexion For $39B Expanding Its Immunology Portfolio

As per reports, AstraZeneca (AZN) a leading Covid-19 vaccine developer and large multinational pharmaceutical firm has agreed to buy Boston-based biotechnology firm Alexion (ALXN) for $39 billion strengthening its position in immunology and rare diseases. Alexion shareholders will receive $60/share...

Dec 13, 2020 View Article

Merck ‘s KEYTRUDA® Gains Positive Committee for Medicinal Products for Human Use of the European Medicines Agency Approval

Merck & Co., Inc. (MRK) known as MSD outside the United States and Canada recently announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has released a positive opinion for the approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for th...

Dec 13, 2020 View Article

Walgreens To Announce Fiscal 2021 First Quarter Earnings On Thursday, January 7, 2021

Reportedly, Walgreen Boots Alliance (WBA) is scheduled to announce its fiscal 2021 first-quarter earnings results on Jan. 7, 2021, Thursday at 7 a.m. ET. The release will be followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. For interested parties, the conference ...

Dec 11, 2020 View Article

UnitedHealth Partners With Lilly To Launch The Study Of Its COVID-19 Antibody Treatment

As per reports, UnitedHealth Group Incorporated (UNH) and Drugmaker Eli Lilly & Co and have come together to conduct a study of Lilly's COVID-19 antibody treatment bamlanivimab in patients who are at risk of becoming severely infected such as those over the age of 65 or the ones suffering from o...

Dec 10, 2020 View Article

Mexico May Order 22 Million Additional COVID Vaccine Doses From J&J

As per reports, Mexico could order an additional 22 million doses of coronavirus vaccine from Johnson & Johnson's Janssen unit, signed under a memorandum of understanding giving it the option of ordering additional doses, informed the Deputy Health Minister Hugo Lopez-Gatell. Recently, Mexico be...

Dec 09, 2020 View Article

8k Reveals That Atossa Therapeutics (ATOS) Has Entered Into An Agreement with Dana-Farber Cancer Institute, Inc.

An 8k was filed today at sec.gov by Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19 (website: www.atossatherapeuti...

Nov 30, 2020 View Article

An Interesting Argument Surfaces For Treating Coronavirus Patients Prior To Requiring Hospitalization

Recently, the Wall Street Journal published an interesting article expressing the argument that our healthcare system would be "less burdened" if coronavirus patients were treated prior to requiring hospitalization and suggesting that their are therapeutic options that patients can take themselves ...

Nov 30, 2020 View Article

Merck To Buy Privately-held, Clinical-stage Biopharmaceutical Company OncoImmune Adding To Suite Of Clinical Programs For SARS-CoV-2/COVID-19

As per reports, Merck & Co., Inc. (MRK) to acquire a privately-held, clinical-stage biopharmaceutical company, OncoImmune in a definitive agreement where Merck, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash through a subsidiary. OncoImmune sha...

Nov 30, 2020 View Article

UnitedHealth Group To Hold Its Annual Investor Conference On December 1

Reportedly, UnitedHealth Group Incorporated (UNH) is scheduled to hold its annual Investor Conference virtually with analysts and institutional investors starting at 9:00 a.m. ET on Tuesday, December 1, 2020. The senior leaders will discuss the company’s progress in regards to the development of t...

Nov 30, 2020 View Article

Walgreen Boots Alliance Introduces 30-Minute Pickup

As per reports, Walgreen Boots Alliance (WBA) offers 30 minutes pick-up from placing an online order for health and wellness products from its stores under its loyalty program which has more than 100 million members in addition to at-home delivery and discounts on prescription drugs. Earlier this w...

Nov 24, 2020 View Article

Global Infertility Industry Focused Medical Device Firm INVO Bioscience Makes Strategic Move To Add Scientific Advisory Board

Sarasota-based INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO") is an innovative medical device company developing solutions for the global infertility industry. INVO's goal is to increase access to care and expand fertility treatment across the globe while seeking to lower the cost and increase the av...

Nov 19, 2020 View Article

Johnson & Johnson Broadens Relationship With Biomedical Advanced Research and Development Authority With Regards To Phase 3 Of COVID-19 Vaccine Candidate

Reportedly, Johnson & Johnson (JNJ) has expanded its partnership with the Biomedical Advanced Research and Development Authority (part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services) under its Janssen Pharmaceutic...

Nov 16, 2020 View Article

Amgen, AstraZeneca Experimental Asthma Drug Shows Promise

Reportedly, Drugmakers Amgen Inc. (AMGN) and AstraZeneca Plc (AZN) announced that a crucial trial found that their experimental medication tezepelumab largely reduced asthma attacks for people suffering from severe forms of the respiratory condition compared to a placebo. The patients were also rece...

Nov 13, 2020 View Article

INVO Bioscience Announces Pricing of Follow-on Public Offering & Listing on the NASDAQ Capital Market

Thursday after the markets closed, INVO Bioscience, Inc. (Nasdaq: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a public offering price of $3.20 per share. Th...

Nov 13, 2020 View Article

As The Coronavirus Pandemic Surges Pfizer’s Vaccine Gives Hope, Eli Lilly’s Antibody Gets FDA Emergency Use Nod & Atossa’s Nasal Spray Trial Progresses

The coronavirus pandemic continues to surge across the world. On Tuesday, it was reported that 51.2M cases have been recorded where 33.5M people have recovered and 1.27M people have died worldwide. In the US, we now have recorded 10.2M cases and ~239k Americans have died from the coronavirus. ...

Nov 11, 2020 View Article

Merck Enters Acquisition Deal With VelosBio To Improve Oncology Pipeline

Reportedly, Merck & Co., Inc. (MRK) and VelosBio Inc have entered a definitive agreement under which Merck, will acquire all outstanding shares of VelosBio for $2.75B in cash through a subsidiary, subject to certain customary adjustments. VelosBio, a private owned clinical-stage biopharmaceut...

Nov 06, 2020 View Article

UnitedHealth Group Announces Cash Dividend

Reportedly, the board of UnitedHealth Group Incorporated (UNH) has announced a cash dividend of $1.25 per share payable on December 15, 2020, to all common stockholders as of the close of business on December 7, 2020. Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified ...

Nov 05, 2020 View Article

Merck Beats Q3 Expectations & Raises Outlook As Keytrada Sales Drive

As per reports, Merck & Co., Inc. (MRK) reported Q3 profits last month performing ahead of market estimates, as it expects the majority of the blow from the ongoing Covid-19 pandemic to now be behind it. Merck earned $1.74 per share, beating analysts’ average estimates of $1.44 per share. S...

Nov 05, 2020 View Article

Natural Killer (NK) Cell-based Immunotherapy Firm Kiadis Reaches Buyout Agreement With Sanofi (SNY)- Who’s Next?

Recently, natural killer (NK) cell-based immunotherapy has emerged as a promising therapeutic approach for solid tumors and hematological malignancies. NK cells are innate lymphocytes with an array of functional competences, including anti-cancer, anti-viral, and anti-graft-vs. -host disease potenti...

Nov 02, 2020 View Article

Pfizer Reports Declining Sales For Third-Quarter, Narrows Yearly Earnings Range

As per reports, Pfizer (PFE) released Q3 earnings recently, reporting sales of $12.13B and EPS of 72 cents per share. The analysts were expecting EPS of 69 cents per share on $12.3 billion in sales. The company narrowed its yearly earning guidance to $2.88-$2.93 a share on revenue of $48.8 billion ...

Nov 02, 2020 View Article

Dr. Quay Publishes Paper Documenting That SARS-CoV-2 Pandemic Began at General Hospital of Central Theater Command of People’s Liberation Army

A paper was published recently on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS), which illuminates new scientific observations and conclusions documenting that the SARS-CoV-2 pandemic began at...

Oct 28, 2020 View Article

PROGRESS REPORT: Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID-19

With the soaring numbers of worldwide coronavirus cases being reported daily with no viable vaccine realistically up for near term approval we need to find better solutions to treat patients that are infected. Recently, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopha...

Oct 28, 2020 View Article

Amgen Reports Q4 Earnings- Lowers 2020 Earnings Guidance

U.S. biotechnology company, Amgen (AMGN) reported Q4 earnings this week, reporting a 2% drop in product sales due to competition from lower-cost generic drugs and biosimilars. Earnings Highlights: Sales for the quarter totaled $5.88 billion. Total revenue dropped 1% to $6.2 billion, ahead of ...

Oct 28, 2020 View Article

United Health Foundation Offers $2M Grant To Support Family First Health’s Federally Qualified Health Center

Reportedly, The United Health Foundation has partnered for a three-year $2M grant with Family First Health’s Federally Qualified Health Center at Hannah Penn K-8 school. The partnership is aimed to improve access to health care for children and families and serving vulnerable populations in the K...

Oct 27, 2020 View Article

Walgreens Includes Covid Testing Facility For Children Age 3 & Older

Reportedly, Walgreen Boots Alliance (WBA) has included testing sites for those aged 3 and older, previously testing was available to 18 years and above. Parents and Guardians can reach at Walgreens.com/COVID19Testing to schedule a test for the child along with electric consent and parents are also r...

Oct 26, 2020 View Article

Johnson & Johnson Announces Q3 Earnings, Raises Full-Year Guidance

As per reports, Johnson & Johnson (JNJ) reported Q3 earnings recently, beating Wall Street’s estimates. Earning Highlights: Adjusted earnings of $2.20 per share was reported, higher than the $1.98 per share estimate. The company generated $21.08 billion in revenue, better than $20.2 bil...

Oct 21, 2020 View Article

UnitedHealth Reports Q3 Earnings, Raises Annual Profit Forecast

Reportedly, the UnitedHealth Group Incorporated (UNH) announced its Q3 earnings this week beating estimates, the company raised its annual profit forecast pushed by growth in its Optum unit that deals in drug benefits. UnitedHealth alarmed demand for deferred services in May and June leading to hi...

Oct 20, 2020 View Article

NeuBase Therapeutics (Nasdaq: NBSE) Adds Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to SAB

Pittsburgh-based NeuBase Therapeutics (NASDAQ: NBSE) is a biotech firm that is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combini...

Oct 13, 2020 View Article

Honeywell To Provide Individual PPE Packs For Panthers Fans For a Safer Stadium Experience

Reportedly, Honeywell (HON) has collaborated with NFL's Carolina Panthers, in an initiative to protect players, fans, and staff this season by providing a safer stadium experience amid the pandemic. Honeywell is providing an additional layer of safety to fans entering the stadium by providing them d...

Oct 08, 2020 View Article

J&J Enters Organizes Deal With Michigan’s Grand River Aseptic Manufacturing For Its COVID-19 Vaccine

Johnson & Johnson (JNJ) has entered a manufacturing deal with Michigan-based, Grand River Aseptic Manufacturing Inc for its SARS-CoV-2 vaccine candidate, which is being developed with partial funding from the U.S. government, as per reports. Recently, J&J launched a late-stage trial of its ...

Sep 29, 2020 View Article

Amgen’s Experimental Drug Shows Sign Of Improvement In Lung Cancer Patients With KRAS Gene Mutation

Reportedly, an experimental Amgen Inc (AMGN) drug meant for a specific genetic mutation reduced tumors in 32% of advanced lung cancer patients and 7% with those suffering from colon cancer in an early-stage trial. The drug sotorasib was given to lung cancer patients for 6.3 months and 4 months for c...

Sep 25, 2020 View Article

Amgen & Eli Lilly Enter Global Antibody Manufacturing Agreement For COVID-19 Antibody Therapies

As per reports, Eli Lilly & Company and Amgen have entered an agreement for a global antibody manufacturing to increase global supply capacity for Lilly's potential COVID-19 treatments. Lilly is currently researching a number of potential neutralizing antibodies for the prevention/treatment or b...

Sep 23, 2020 View Article

A Must Read: “Stay Safe: A Physician’s Guide to Survive Coronavirus” – A Resource That Will Help Protect Your Family Against the Coronavirus

Unfortunately, there are currently over 31.5 million confirmed coronavirus cases worldwide and over 967,000 related deaths! Recently, the director of the Centers for Disease Control and Prevention told lawmakers that he doesn't expect a potential COVID-19 vaccine to be available for most Americans...

Sep 23, 2020 View Article

Walgreens Introduces Personalized Pain Management Offering And Owned Brand Arthritis Pain Relief Gel

Walgreen Boots Alliance (WBA) announced the launch of diclofenac gel, an over-the-counter original prescription-strength arthritis pain relief in topical form for people suffering from chronic and acute pain. Specially trained Walgreens pharmacists, with support from the Global Healthy Living Founda...

Sep 17, 2020 View Article

PROGRESS REPORT: Atossa Therapeutics (Nasdaq: ATOS) Announces Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, plans to develop its nasal spray to potentially help prevent COVID...

Sep 17, 2020 View Article

J&J Janssen Unit Begins Mid-Stage COVID-19 Vaccine Trials In Spain

Reportedly, Johnson & Johnson's (JNJ) Janssen unit began mid-stage trials of its COVID-19 vaccine in Spain on 14th September 2020. 190 people are reported to take part in the country's trials, which will take place in three hospitals and will be concluded by Sept. 22. Phase II trials are being ...

Sep 17, 2020 View Article

UnitedHealthcare And Optum Come Forward With Assistance To Support People Affected By Ongoing Wildfires In California, Oregon, Washington, etc.

As per reports, UnitedHealthcare (UNH) and Optum have come forward to help people affected by the ongoing wildfires across parts of California, Oregon, Washington, and several other Western States offering support to health plan participants with health arrangements to access care and early prescrip...

Sep 17, 2020 View Article

Latin America To Come Forward With 1/3 Of J&J’s COVID-19 Vaccine Trial Volunteers

Reportedly, Johnson & Johnson (JNJ) is expecting 20,000 volunteers for late-stage human trials for its experimental coronavirus vaccine from Latin America, one of the worst affected regions by the pandemic making it an attractive testing sites for vaccine developers as it is an easier option to ...

Sep 17, 2020 View Article

Chile & Peru Added To The List Of Johnson & Johnson’s Latin America COVID-19 Vaccine Trials

As per reports, Johnson & Johnson (JNJ) will be adding Chile and Peru to the Latin nations where it plans to conduct Phase III trials for its vaccine against COVID-19. The trial involves 60,000 volunteers from Brazil, Chile, Colombia, and Peru, coordinated by J&J's pharmaceutical unit Jansse...

Aug 30, 2020 View Article

UnitedHealthcare To Serve Hoosier Care Connect Program Beneficiaries For State Of Indiana

As per reports, The Indiana Family and Social Services Administration has chosen UnitedHealth Group Incorporated (UNH) to administer its Hoosier Care Connect program. The program is designed to help blind and disabled members, eligible aged, and foster population. The four-year contract to begin on ...

Aug 29, 2020 View Article

Johnson & Johnson’s Diabetes Drug Relieved Of Boxed Amputation Risk Warning

As per reports, the U.S. Food and Drug Administration has removed the boxed warning about amputation risk for Johnson & Johnson's (JNJ) diabetes drug, Invokana. Amputations have been observed as the agency’s harshest warning. Approved in 2017, Invokana is advised to be used with diet and exerc...

Aug 26, 2020 View Article

Free Registration Now Open for NeuBase Therapeutic’s CEO, Dietrich A. Stephan, Ph.D., Tribe Public Presentation and Q&A Webinar Event on August 26, 2020

Tribe Public announced that Dietrich Stephan, Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ: NBSE), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, will present at Tribe Pu...

Aug 25, 2020 View Article

Johnson & Johnson Struck $6.5B Cash Buyout For Autoimmune Disease Developer Momenta

As per reports, Johnson & Johnson (JNJ) is set to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to strengthen its portfolio of drugs for hard-to-treat autoimmune diseases. Treatments specializing in autoimmune conditions have gained importance and have fetched billions of dollars in ...

Aug 23, 2020 View Article

Johnson & Johnson Poised To Commence 60K Participant Phase 3 COVID-19 Vaccine Trial In September

As per reports, Johnson & Johnson (JNJ) is set to commence the large scale late-stage trial of its potential coronavirus vaccine next month. The trial is looking forward to enrolling up to 60,000 healthy people randomly selected from the age of 18 years and above across 180 locations in the U.S....

Aug 22, 2020 View Article

Britain Secures Relationship With J&J & Novavax For Potential COVID-19 Vaccine Supplies

As per reports, Britain has secured a deal for the potential COVID-19 vaccines from Johnson & Johnson (JNJ) and Novavax Inc. The latest addition brings Britain's total number of doses to 340 million, with options for millions more for its population of 66 million. "For now that is probably th...

Aug 21, 2020 View Article

Atossa Announces Advancement of COVID-19 Novel Nasal Spray Drug Treatment Candidate – “Focusing On Moving COVID-19 Clinical Studies As Quickly As Possible”

As of Monday night, worldwide coronavirus cases now total 22,049,426 with 777,439 deaths and 14,791,859 people have been reported to have recovered. In the US, we lead the world as we now have 5,612,027 reported cases, 173,716 deaths, and 2,973,587 have now recovered. With that said, the world co...

Aug 18, 2020 View Article

Pfizer, BioNTech Adds Japan To Coronavirus Vaccine Supply List For First Half of 2021

As per reports, Pfizer (PFE) and BioNTech SE to supply 120 million doses of their experimental coronavirus vaccine to Japan in the first half of 2021. Financial details of the agreement were not disclosed. Earlier, The United States also entered a similar deal with Pfizer and BioNtech for 100 millio...

Aug 06, 2020 View Article

Atossa Therapeutics Announces Interim Findings Following 18 Months Expanded Access Single-Patient Study of Atossa’s Endoxifen In Breast Cancer

Thursday, July 30th, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced interim findings following 18 months...

Jul 31, 2020 View Article

Pfizer And BioNTech Pushing Forward With Pivotal Global Study Of COVID-19 Vaccine Candidate

As per reports, U.S. drugmaker Pfizer (PFE) and German biotech BioNTech begin a pivotal global study to assess the performance of its COVID-19 vaccine which it calls BNT162b2. Successful completion of the study will enable the companies to submit the vaccine for regulatory approval by early October,...

Jul 30, 2020 View Article

Britain Enters Deals For Possible COVID-19 Vaccine Doses From Pfizer/BioNTech, Valneva

As per reports, Britain has entered deals to buy 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc (PFE) and BioNTech, and French group Valneva. Britain has signed in to procure 30 million doses of the early to mid-stage trials BioNTech/Pfizer vaccine and 60 million d...

Jul 23, 2020 View Article

Pfizer Enters $1.95B Deal To Provide U.S. With COVID-19 Vaccine Doses

Reportedly, Pfizer (PFE) has entered a $1.95 billion deal to provide 100 million doses of a COVID-19 vaccine to the U.S. government, with an additional right to purchase more 500 million doses. The company said that the Americans will be treated with the vaccine for free. The vaccine is in developme...

Jul 23, 2020 View Article

UnitedHealth Released Q2 Earnings, Warns Of Rising Costs But Sticks To Forecast

UnitedHealth Group Incorporated (UNH) reported earnings for Q2 ending June 30 and stuck to its full-year forecast, as per reports. The company warned of rising costs later this year as Americans catch up on less urgent surgeries put on hold by the coronavirus pandemic. The Insurer also expects fut...

Jul 23, 2020 View Article

INVO Bioscience Takes Key Commercialization Step With Registration of INVOcell in Turkey

“As the world’s only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility industry.”- Steve Shum, CEO of INVO Bioscience (INVO) INVO Bioscience, Inc. ( INVO) (“INVO”) is an innovative medical devi...

Jul 16, 2020 View Article

Atossa Therapeutics Announced Successful In Vitro Testing Of Its COVID-19 Nasal Spray Formulation Treatment Candidate

According to a New York Times database, the U.S. COVID-19 pandemic has rapidly increased in 41 states over the past 2 weeks and reached 3.5M total infections as of Wednesday. Along with this growing concern and working to towards a treatment for COVID-19, Seattle-based Atossa Therapeutics, Inc. (...

Jul 16, 2020 View Article

Walgreens & VillageMD Partnering To Open Up To 700 Full-Service Doctor Offices Attached to Drug Stores in US

Reportedly, Walgreen Boots Alliance (WBA) is partnering with primary care provider VillageMD to offer doctor offices attached to its drugstores across the United States as a move to expand and offer healthcare services under one roof. The company is planning to open 500 to 700 physician-led primary ...

Jul 14, 2020 View Article

Atossa Therapeutics Advancing With Key Clinical & Regulatory Hires With Focus On COVID-19 & Breast Cancer Programs

Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced Wednesday that it has hired key personnel i...

Jul 09, 2020 View Article

Walgreens Restarts Immunization Services

As per reports, Walgreens (WBA) has restarted immunization services, taking care of all safety measures for pharmacy team members and patients. The changes comply with the updated U.S. Centers for Disease Control and Prevention (CDC) guidelines keeping in mind the flu season ahead, which may coi...

Jun 22, 2020 View Article

A Vista Partners Interview With Steve Shum CEO of INVO Bioscience Regarding Increasing Access To Care For Fertility Treatment

As compared to other countries, public payers in the US for the most part do not cover infertility services and, while a few state mandates for some coverage are in place, most private plans are exempted, leaving the majority of patients to pay out of pocket for their infertility care. With that min...

Jun 18, 2020 View Article

Eli Lilly Completes Successful Phase 3 Study On Breast Cancer Relapse

Reportedly, Eli Lilly (LLY), an American pharmaceutical company is expected to grab a significant share of Pfizer's (PFE) breast cancer treatment market after the completion of a successful Phase 3 study of Verzenio. The researchers at Eli Lilly tested Verzenio in combination with standard endocrin...

Jun 18, 2020 View Article

Fate Therapeutics Announces Completion of Public Offering of Common Stock At $28.31/share & Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the cl...

Jun 12, 2020 View Article

Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201

SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that the manus...

Jun 11, 2020 View Article

Will The Coronavirus Infect Every Human On The Planet? Atossa’s CEO Says…

In a recent article published at Best Life Online, Steven Quay M.D., Ph.D., the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and COVID-19 therapeutics, stated "corona...

Jun 04, 2020 View Article

European Health Regulators Bless J&J’s Ebola Vaccine

As per reports, Johnson & Johnson's (JNJ) two-dose experimental vaccine for Ebola in the European Union has received approval from the European health regulators. The vaccine is prepared to target the Ebola strain that causes the disease in most people, J&J submitted the approval application...

Jun 04, 2020 View Article

Atossa Therapeutics Teams With Nasal Spray Specialist Summit Biosciences To Develop Proprietary Drug Candidate AT-301 Intended to Prevent COVID-19 & Treat Early Cases

Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced on Thursday, May 28th that it has begun the...

May 29, 2020 View Article

Successful Results Announced From In Vitro Testing of AT-H201, Atossa’s Proprietary COVID-19 Drug Candidate

Earlier today, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced the successful results from in vitro...

May 20, 2020 View Article

Johnson & Johnson’s Baby Powder Will Continue To Be Sold in U.K

Reportedly, healthcare giant Johnson & Johnson (JNJ) to continue selling its talc-based Johnson's Baby Powder in the UK and the rest of the world, after facing ban in the US and Canada. The component talc which is mined from the earth and is found close to that of asbestos, known to cause cance...

May 20, 2020 View Article

Seattle-based Biotech Firm Atossa Therapeutics (ATOS) Announces Q1 Progress

Seattle-based biotech firm Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need announced its Q1 2020 Financial Results and confirmed the following progress: Launched a new dr...

May 14, 2020 View Article

J&J Beat Estimates, Lowers Full Year Guidance, & Raises Dividend

Johnson & Johnson (JNJ) recently released its quarterly earnings which beat market estimates. JNJ also made the decision to raise its dividend from $.95 cents a share to $1.01. The company forecasted 2020 adjusted earnings will reach the $7.50 to $7.90 per share level, much lower than its prior ...

May 13, 2020 View Article

Fertility Benefits Management Company Progyny, Inc. (PGNY) Realized A 72% Increase in Q1 2020 Revenue

Today, Progyny, Inc. (PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, announced its financial results for the 3-month period ended March 31, 2020, as compared to the three-month period ended March 31, 2019. PGNY co...

May 13, 2020 View Article

Pfizer Realizes Decline In Q1 Sales But Exceeds Expectations

Pfizer (PFE) reported first-quarter earnings on Tuesday, April 28, 2020, beating Wall Street Expectations. The drugmaker announced an adjusted EPS of 80 cents per share, 7 cents higher than Wall Street estimates. The company recorded total sales of $12 billion, an 8% decline in comparison to a year ...

May 06, 2020 View Article

UnitedHealth Group Beats Quarterly Profits

Dow 30 component, UnitedHealth Group Incorporated (UNH) released quarter earnings recently beating analyst expectations and upholding its 2020 outlook boosted by strength across its businesses. The company announced the medical loss ratio of 81.0%, beating analysts’ estimates of 81.57% for the qua...

May 05, 2020 View Article

COVID-19 HOPE Clinical Study Update: Atossa Therapeutics (ATOS) Contracts with NYC Health + Hospitals/Metropolitan

“Managing patient care and ventilator use has become a major challenge. We have an urgent need for a therapy to reduce reliance on ventilators and we are looking forward to playing a key role in what could be a much-needed solution for our sickest COVID patients.” commented Getaw Hassen, M.D.,...

Apr 27, 2020 View Article

UnitedHealth Group Led Initiative Providing Coventor, A Newly Invented “Light” Ventilator, During COVID-19 Pandemic

As per reports, UnitedHealth Group Incorporated (UNH) has teamed up with Boston Scientific, Medtronic, and the University of Minnesota for the distribution of 3k newly invented "light" ventilators to meet the limited stock of ventilators during the COVID-19 pandemic emergency. UnitedHealth Group is ...

Apr 24, 2020 View Article

Vios Fertility Institute Highlights INVO Bioscience’s INVOcell Infertility Treatment On The Morning Blend

April 19th-25th is National Infertility Awareness Week. Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are being treated, but help is on the way... This week, The Morning Blend aired an interview on WTMJ-4 Milwaukee where Dr. Ellen Hayes, a R...

Apr 23, 2020 View Article

The COVID-19 HOPE Trial Is Believed To Be The First Pharmaceutical Study Seeking To Address Getting Patients Off Mechanical Ventilators & Reducing High Death Rate

The number of worldwide coronavirus cases has grown to more than 2.4 million while the number of worldwide deaths have jumped to north of 170,000. Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), announced today that it has applied to the FDA for approval to commence a clinical stu...

Apr 20, 2020 View Article

3M Files Lawsuit Against Unauthorized Vendor Selling 3M-Branded N95’s At 500-600% Premiums

As per reports, 3M (MMM) has filed a lawsuit in federal court in Manhattan against New Jersey-based, Performance Supply LLC on Friday alleging that the company posed itself as an authorized vendor of 3M-branded N95 respirators and offered millions for sale to New York City officials at prices much h...

Apr 15, 2020 View Article

3M To Ramp Up Production Of Face Masks After Defense Production Act Orders

Reportedly, 3M (MMM) is continuing to increase the production of face masks after President Trump announced that he was invoking the Defense Production Act to get the company production rolling for more face masks. 3M to work closely with the Federal Emergency Management Agency to produce the masks....

Apr 07, 2020 View Article

FOX NEWS INTERVIEW TODAY: “Atossa Therapeutics'(ATOS) CEO Steven Quay MD, PhD Regarding New COVID-19 Hope Trial”

Steven Quay M.D., Ph.D. is the founder, Chairman & CEO of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions. He received his M.D. and Ph.D. from The ...

Apr 06, 2020 View Article

INVO Bioscience Appoints Christopher A. Myer as Vice President Of Business Development – Americas

INVO Bioscience, Inc. (INVO) is a medical device company focused on treating infertility with its FDA-cleared INVOcell® product. INVOcell is the first intravaginal culture device used for the incubation of eggs and sperm during fertilization and early embryo development using the women's body fo...

Apr 06, 2020 View Article

Fate Therapeutics (FATE) Shares Jump In Aftermarket Trading Post Announcing Worldwide Collaboration with Janssen

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Jansse...

Apr 02, 2020 View Article

INVO Bioscience Reports A 199% Increase in Topline Revenues in 2019

INVO Bioscience, Inc. (INVO) is a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers pat...

Mar 31, 2020 View Article

Walgreens Increases On-Demand Delivery Services Across Stores With Postmates Amid COVID-19 Pandemic

As per reports, Walgreen Boots Alliance (WBA) has partnered with Postmates to address the rising need for home delivery nationwide amid the coronavirus outbreak. Consumers can now get health and wellness items including some OTC products medications, household essentials from more than 7,000 Walg...

Mar 31, 2020 View Article

J&J Announces Lead COVID-19 Vaccine Candidate Committing More Than $1B To Co-fund Development

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. Johnson & Johnson (JNJ) announced that it has selected a lead COVID-19 vaccine candidate whic...

Mar 30, 2020 View Article

Intel Is Providing Money & Equipment For COVID-19 Relief Programs In Oregon & Beyond

Reportedly, Intel Corporation (INTC) is working to provide money and equipment to health agencies and other COVID-19 relief programs. The company informed that $1 million out of $4 million announced this week will back groups in Oregon for essential services and equipment. The following community-ba...

Mar 30, 2020 View Article

NeuBase Expects To Announce Pharmacokinetic Data In Non-human Primates & In-vitro Pharmacodynamic Data For Its PATrOL™ Platform Next Week

Pittsburgh-based NeuBase (NASDAQ: NBSE) has developed a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase believes that it has improved gene silencing therapies to include th...

Mar 26, 2020 View Article

Procter & Gamble’s Vicks Contributes $1M Funding To Assist Front Line Health Workers of COVID-19

The Procter & Gamble Company (PG)'s Vicks® family of cold and flu brands – NyQuil™, DayQuil™ and VapoRub™ are donating $1 million to Direct Relief, a humanitarian aid organization aiming to improve the health and lives of people affected by poverty or emergencies, including COVID-19. T...

Mar 24, 2020 View Article

UnitedHealth Group Announces Date For Q1 2020 Earnings & Call

As per reports, UnitedHealth Group Incorporated (UNH) will release its Q1 2020 financial results on Wednesday, April 15, 2020, before the market opens. The company to host a teleconference at 8:45 a.m. ET to be webcast on the Investors page of the company’s web site at (www.unitedhealthgroup.com)...

Mar 23, 2020 View Article

Walgreens Revises Store Operating Hours Beginning March 19

Walgreen Boots Alliance (WBA) announced revised operating hours for its stores and pharmacy beginning from Thursday, March 19 amid the growing COVID-19 pandemic. The revised operating hours to be implemented keeping in mind the safety of its store team members and ensuring to meet its customer's ne...

Mar 18, 2020 View Article

Pfizer To Co-Develop Potential COVID-19 Vaccine With BioNTech

As per reports, U.S. drugmaker Pfizer Inc and Germany's BioNTech SE have come together to develop a potential COVID-19 medicine using BioNTech's mRNA-based drug development platform. The drugmaker to start the collaboration immediately, the terms and conditions to be finalized over the next few week...

Mar 17, 2020 View Article

Infertility Treatment Innovator INVO Bioscience Makes Strategic Branding Move – Changes Trading Symbol to INVO

The Global Fertility Services market size is expected to reach $36 billion with a CAGR of 8.5% by 2023, according to a recent report by Market Research Future (MRFR) highlighted in Forbes. With that being the case, over the last handful of years, we are seeing growing investor interest and a growing...

Mar 16, 2020 View Article

Atossa Therapeutics Due To Meet FDA To Discuss The Clinical Development of Oral Endoxifen to Reduce Mammographic Breast Density (MBD)

MBD is an emerging public health issue affecting over 10 million women in the U.S. MBD is a recognized risk factor for future breast cancer and there is no approved therapy to reduce MBD. High-risk women are usually advised to have more frequent or sophisticated mammograms and to make lifestyle c...

Mar 13, 2020 View Article

INVO Bioscience Continues Global Buildout With Hire Of Yve Lyppens As Director Of Business Development Asia Pacific

According to the CDC's website, in general, infertility is defined as not being able to get pregnant (conceive) after one year (or longer) of unprotected sex. Because fertility in women is known to decline steadily with age, some providers evaluate and treat women aged 35 years or older after 6 mont...

Mar 11, 2020 View Article

UnitedHealthcare & Optum Stepping Forward To Offer Care & Support To Members Amid COVID-19

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employer...

Mar 10, 2020 View Article

Thermo Fisher Scientific To Buy Global Provider of Molecular Diagnostics QIAGEN for ~$11.5B

Reportedly, Thermo Fisher Scientific Inc. (TMO), the world leader in serving science. is set to acquire Qiagen (QGEN), a Netherlands-based holding company and global provider of molecular diagnostics and sample preparation technologies. The deal received approval by the boards of directors, as well...

Mar 05, 2020 View Article

MIT’s Dr. Susan Hockfield To Join Pfizer’s Board Of Directors

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. As per reports, Pfizer declared the election of Dr. Susan Hockfield to its Board of Directors. Dr. Hockfield will be added immediately & will also b...

Mar 04, 2020 View Article

Homewood’s America Institute of Reproductive Medicine Is Reducing IVF Costs With INVO Bioscience’s INVOcell Device

If you have never heard of a town called Homewood then you are probably not alone. Homewood is a town that is located adjacent to Birmingham, AL and has an unremarkable population of approximately 26,000 on a good day. So why am I interested? Simply put, Homewood is the home of the America Instit...

Mar 04, 2020 View Article

Has Pfizer Identified Compounds For Treatment Of Coronavirus?

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Reportedly, Drugmaker Pfizer has informed that it has identified certain antiviral compounds in development that has the potential to inhibit coronavir...

Mar 03, 2020 View Article

Atossa Therapeutics Achieves Important Milestone In Mammographic Breast Density & Gilead Puchases Forty-Seven, Inc. For $4.9B

MBD is an emerging public health issue affecting more than 10 million women in the United States. Studies conducted by others have shown that MBD increases the risk of developing breast cancer, and reducing MBD can reduce the incidence of breast cancer. Today Atossa Therapeutics, Inc. (Nasdaq: ...

Mar 02, 2020 View Article

Shares of Avadel Pharmaceuticals plc (AVDL) Are Surging In Concert With $65M Private Placement Led By Jefferies, Piper Sandler, and Stifel

Shares of Avadel Pharmaceuticals plc (AVDL) are surging today hitting an intraday high of $9.64/share ( a new-52-wk an all-time high) and currently is trading at $9.12/share, +28%. Their 52-wk range is $1.03 - $9.64. Avadel is a company focused on developing FT218, an investigational, once-nightly f...

Feb 21, 2020 View Article

Fate Therapeutics (FATE) Hits New All-Time High During Investor Conference Schedule

Shares of Fate Therapeutics, Inc. (FATE) hit an all-time new high today reaching $30.60/share which puts an approximate $2.3 Billion Market Cap. The 52-wk range is $12.59 - 30.60. Fate is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies f...

Feb 21, 2020 View Article

Is There An Intersect Between Breast Cancer & Heart Disease?

The growing awareness among Americans with respect to breast cancer and heart disease is quite evident, pink ribbons and red dresses have helped millions of men & women become aware of the risks, precautions, and prevention related to the above two most common illnesses. However, not many know ...

Feb 20, 2020 View Article

INVO Bioscience Progresses With Hiring of Inger Britt Carlson, Ph.D., Former Global Director of CooperSurgical Fertility & Genomics

INVO Bioscience (IVOB), under the guidance of newly appointed CEO Steve Shum (Q4, 2019), continues to make progress towards building a vibrant and growing organization in the fertility space. Today, INVO Bioscience, Inc. (IVOB), a publicly-traded medical device company focused on treating infertili...

Feb 13, 2020 View Article

China Pushes $10.26B Forward to Make Sure Public Not Hampered Financially In Dealing With Coronavirus Outbreak

According to Reuters today, "China's finance ministry said on Sunday all levels of government had allocated a total of 71.85 billion yuan ($10.26 billion) as of Saturday afternoon to fight coronavirus....

Feb 09, 2020 View Article

Nonfarm Payrolls Skyrocket 225k In January, Exceeds Wall Streets Estimates

The U.S. jobs market powered on to more gains, as nonfarm payrolls rose 225k for January exceeding Wall Street estimates. While the unemployment rate walked higher to 3.6% in concert with the labor force participation rate rising +.2 percentage points to 63.4%. The improvement is thought to be ...

Feb 07, 2020 View Article

INVO Bioscience Receives IRB Approval to Commence INVOcell Clinical Trial To Gain Expanded Labeling Including Live Birth After 5-Days of Continuous Vaginal Incubation

Sarasota-based INVO Bioscience, Inc. (IVOB) is a medical device company focused on treating infertility with its FDA-cleared INVOcell® product. the INVO® Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead produc...

Feb 05, 2020 View Article

Interview with Atossa Therapeutics’ Kyle Guse On World Cancer Day “Transforming Breast Cancer Treatment”

Every February 4th is World Cancer Day, the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective, and government action, they are working to reimagine a world where millions of pre...

Feb 04, 2020 View Article

Dow 30 Component Pfizer Reports Quarterly Earnings But Falls Short of Expectations

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer reported quarterly profits on Tuesday, falling short of market estimates for the first time in the last two years. Sale of its patent drug Lyrica...

Feb 01, 2020 View Article

Symphonix Health Insurance, A UnitedHealth Care Company Credited With Financial Strength Rating of A

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employer...

Jan 30, 2020 View Article

INVO Bioscience To Attend The Arab Health Exhibition The Largest Gathering In The MENA Region

The Arab Health Exhibition is the largest and most comprehensive gathering for the healthcare industry in the MENA (the Middle East and North Africa) region. It first took place in Dubai, the United Arab Emirates in 1975 and is now recognized as the second-largest healthcare exhibition and congress ...

Jan 27, 2020 View Article

Breast Cancer Focused Atossa Therapeutics CEO Dr. Steven C. Quay Issued An Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. This week Atossa Therapeutics' President and CEO Dr. Steven C. Quay Issued an Annual Lette...

Jan 24, 2020 View Article

Johnson & Johnson Reports Earnings, Beats Wall Street Profit Estimates But Misses On Revenue

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. Johnson & Johnson reported its fiscal Q4 profit results, beating Wall Street’s expectations...

Jan 24, 2020 View Article

Walgreens Gains First Enterprise-Wide URAC Specialty Pharmacy Accreditation

Walgreen Boots Alliance (WBA) is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Reportedly, Walgreens has received the first enterprise-wide URAC accreditation in Specialty Pharmacy f...

Jan 24, 2020 View Article

“Day 4 JPM2020 Complete & Broad Markets Rise To New Record Levels” – Vista Partners Daily Market Recap For January 16, 2020

Day 4 of the 38th Annual J.P. Morgan Healthcare Conference in San Francisco is now complete. I logged in a few more meetings with companies in the biotech and healthcare sectors & also attended the Tribe Public Keynote Speaker luncheon event where Dietrich Stephan Ph.D., CEO of Pittsburgh-ba...

Jan 16, 2020 View Article

INVO Bioscience (IVOB) Signs First JV To Operate Dedicated INVOcell Fertility Clinics in India

The INVOcell system (picured below) is a novel fertility treatment that uses a woman's own body as a natural incubator for the incubation of eggs and sperm during fertilization and early embryo development. INVO Bioscience, Inc. (IVOB) believes this process is cost-effective and has shown comparab...

Jan 16, 2020 View Article

“Day 3 JPM2020 – Momenta & IsoRay Surge – Phase One Trade Deal Signed” – Vista Partners Daily Market Recap For January 15, 2020

Day 3 of the 38th Annual J.P. Morgan Healthcare Conference in San Francisco is complete and I have logged in another double-digit round of meetings with companies in the biotech and healthcare sectors. I met with interesting companies like CRISPR leader firm Intellia Therapeutics (NTLA) & Millen...

Jan 15, 2020 View Article

“Day 2 JPM2020 – Denali Therapeutics, Momenta Pharmaceuticals & Bellicum Pharmaceuticals Jump ” – Vista Partners Daily Market Recap For January 14, 2020

Day 2 of the 38th Annual J.P. Morgan Healthcare Conference in San Francisco is nearly complete. I met with another 12 companies in the biotech and healthcare sectors including interesting companies like Oncolytics Biotech (ONCY), Syros Pharmaceuticals, (SYRS), Prevail Therapeutics (PRVL) & man...

Jan 14, 2020 View Article

“JPM2020 The S&P 500, Nasdaq & Apple Soar To New Records” – Vista Partners Daily Market Recap For January 13, 2020

The 38th Annual J.P. Morgan Healthcare Conference kicked off today in San Francisco. It is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investme...

Jan 13, 2020 View Article

Towa Pharmaceutical Co. Ltd. To Strengthen Its Global Generic Medicine Business With The Acquisition Of Pensa Investments

As per reports, Kadoma, Osaka Japan-based company Towa Pharmaceutical Co. Ltd. that specializes in generic drugs announced it is acquiring 100% ownership of Pensa Investments, S.L. (Pensa), the generics division of the Spanish pharmaceutical company ESTEVE. The deal to be an all-cash deal with an up...

Dec 27, 2019 View Article

Shares of Atossa Rise After Contracting For Phase 2 MBD Study In Women & An Analyst BUY Recommendation

Breast cancer is the most common cancer in women in the US with more than 268,000 new cases in 2019 according to the American Cancer Society. Legislation has been recently enacted in over 35 states requiring that women be notified if they have Mammographic breast density (MBD) and those ...

Dec 20, 2019 View Article

Pfizer & Astellas Pharma’s XTANDI Gains Supplemental FDA-Approval For The Treatment Of Metastatic Castration-Sensitive Prostate Cancer

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

Dec 18, 2019 View Article

Merck Announced the Acquisition of Cancer-Drug Developer ArQule For $2.7B

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...

Dec 14, 2019 View Article

J&J’s Janssen Pharmaceutical Companies To Provide 200k Ebola Vaccine Regimens to the Republic of Rwanda

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. Reportedly, Johnson & Johnson’s Janssen Pharmaceutical Companies is set to provide 200k Ebo...

Dec 10, 2019 View Article

Breast Cancer Novel Therapeutics Firm Atossa Genetics Will Be Presenting at LD Micro Main Event Conference on Tuesday Dec 10 In LA

Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presenter at the LD Micro Main Event on December 10, 2019, at 12:...

Dec 05, 2019 View Article

Seattle Genetics & Astellas Enter An Agreement With Merck To Assess Effectiveness Of Drug For Metastatic Urothelial Cancer

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...

Dec 05, 2019 View Article

United Health Foundation & The Colorado Center For Nursing Excellence Seeking To Produce Better Behavioral Health Clinical Practice

Reportedly, The United Health Foundation is initiating a $1.5 million grant to the Colorado Center for the next three-years. This will go to support and recruit 39 currently-employed rural Advanced Practice Registered Nurse Behavioral Health Fellows. The move will further go to help the fellows to r...

Dec 03, 2019 View Article

Aslan Skyrockets (+36.13%), NeuBase Therapeutics Pops (+8%), Hecla Bumps (+2.43%) & Market/Manufacturing Drops – Vista Partners Daily Market Recap 12/2/19

The broad markets dropped this first trading day in December in a reaction to the ISM Manufacturing Index report for November which confirmed a 48.1% reading vs. a 48.3% reading for October still south of the Mendoza line for expansion and this did nothing to excite the market. The S&P 500 real...

Dec 02, 2019 View Article

The Latest on Gene Silencing Biotech Firm Arrowhead Pharmaceuticals Fiscal Year 2019 Results

Recently, Arrowhead Pharmaceuticals (ARWR), a company that develops medicines that treat intractable diseases by silencing genes that cause them, announced its earnings report for the quarter ending September 30, 2019. The company hosted a live webcast of the event, a replay of which will be availab...

Dec 01, 2019 View Article

Tech Data Leaps (+12.32%) On Apollo Bid & Broad Markets Take It On Chin! Vista Partners Daily Market Recap 11/29/19

Big Movers Shares of Tech Data (TECD) lept +12.32% today closing at $144.89/share. Private equity firm Apollo Global Management agreed to pay $145/share for TECD on Wednesday, up from its original bid of $130/share of Warren Buffett's Berkshire bid of $140/share from last week. TECD op...

Nov 29, 2019 View Article

Unexpected Key Data Points, AVX Corp (+18.97%), INVO Bioscience (+9.09%) & Broad Markets Rise! Vista Partners Daily Market Recap 11/27/19

Big Movers Shares of AVX Corporation (AVX) jumped +36.37% today. AVX is a leading manufacturer and supplier of advanced electronic components and interconnect, sensor, control, and antenna solutions that yesterday won the South Carolina Life Sciences Pinnacle Award for Organizational Contrib...

Nov 27, 2019 View Article

Arrowhead Pharma, Nutanix, Retail Sector & Broad Markets Rise! Vista Partners Daily Market Recap 11/26/19

Big Movers Arrowhead Pharmaceuticals, Inc. (ARWR), a company that develops medicines that treat intractable diseases by silencing the genes that cause them rose +18.79% today closing at $67.70/share. Yesterday after the close the company hosted the fiscal year 2019 conference call to review t...

Nov 26, 2019 View Article

Select Walgreens Stores To Launch UnitedHealthcare’s Member Medicare Services Centers

Reportedly, UnitedHealthcare and Walgreens are set to launch 14 UnitedHealthcare Medicare services centers within Walgreen stores in Las Vegas, Phoenix, Cleveland, Denver, and Memphis markets in January 2020. The initiative which is part of a multiyear agreement between the companies will allow Walg...

Nov 26, 2019 View Article

The Medicines Company (MDCO), IBB, & Russell 2000 Post Big Wins! Vista Partners Daily Market Recap 11/25/19

Big Movers Novartis (NVS) announced that it is buying The Medicines Company (MDCO) and its experimental treatment inclisiran uses a new approach to lower bad cholesterol in especially hard to treat patients for $9.7B. Shares of MDCO jumped +22.25% closing at $83.80/share. The Ishares Nasdaq ...

Nov 25, 2019 View Article

“Friday Market Drifts Up, Nordstrom & Buffett’s StoneCo Ltd. Surge!” Vista Partners Daily Market Recap 11/22/19

Big Movers Nordstrom (JWM) soared to $37.95/share up +10.58% today after beating Wall Street's expectations as they saw their digital sales drive Q3 performance leading them to revise their guidance upward. A leading provider of financial technology solutions that empower merchants to conduc...

Nov 22, 2019 View Article

“TD Ameritrade Flys On Chuck Schwab Interest” Vista Partners Daily Market Recap 11/21/19

Big Movers According to a plethora of sources, today Charles ("Chuck") Schwab (SCHW) is making a move to combine with rival brokerage firm TD Ameritrade (AMTD), a deal that could be worth more than $25B. It would also create a new behemoth company in the brokerage space with over $5T in combi...

Nov 21, 2019 View Article

New Type of IVF Treatment From Newcomer INVO Bioscience Is Headed To Reno

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. With this in mind, the business, art, & the science of gettin...

Nov 21, 2019 View Article

Will Novartis Acquire Parsippany-based The Medicines Company?

Reportedly, Novartis AG is in talks to acquire Parsippany, New Jersey-based The Medicines Company (MDCO) a developer of a promising cholesterol drug, as per sources. Other potential acquirers have also shown interest in the purchase of Medicines, tripling the value of its shares recently this year ...

Nov 21, 2019 View Article

“No Phase One In 2019? – Target & Neubase Therapeutics Jump!” Vista Partners Daily Market Recap 11/20/19

Big Movers Target Corporation (TGT) jumped +14.06% closing at $126.43/share after crushing earnings expectations and reporting a surge of +4.5% in same-store sales in Q3. Vista Partners recently highlighted a "one-to-watch-stock" in the weekly market recap called Neubase Therapeutics (NBSE),...

Nov 20, 2019 View Article

INVO Bioscience, Developers Of The World’s Only In Vivo FDA Cleared Intravaginal Culture System, Will Host A Live Investor Webcast at 11:00 AM ET (8:00 am PT) on Thursday, November 21, 2019

The business, art, & the science of getting pregnant in today's world is receiving greater focus from venture capitalists, private equity firms, mutual funds, and family offices. This interest is evidenced in the increasing number of startups innovating in the fertility space in recent years a...

Nov 19, 2019 View Article

Merck Acquires (Developer Of Selective Small Molecule Agonists to TRPML1) Calporta Therapeutics

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...

Nov 19, 2019 View Article

INVO Bioscience, Developers of INVOcell® (The World’s Only In Vivo Intravaginal Culture System), Reports Q3 Progress

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. The INVOcell system (pictured above) is a novel fertility treat...

Nov 14, 2019 View Article

Google Enters Agreement With Ascension, The Largest Catholic Health System In The World

Reportedly, Google (GOOG) has entered an agreement with Ascension, its biggest cloud-computing customer in healthcare to date. Ascension, having operations over 150 hospitals across the United States is expected to move some data and analytics tools in its facilities to Google's servers. The deal wi...

Nov 14, 2019 View Article

Breast Cancer Treatment Developer Atossa Genetics Announced Recent Q3 Developments & Upcoming Significant Q4 2019 Milestones

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the third quarter ended September 30, 2019, and provides an update on recent co...

Nov 13, 2019 View Article

INVO Bioscience Enters New Commercialization Agreements For INVOcell®, The World’s Only In Vivo Intravaginal Culture System, In Eurasia (Turkey & Jordan)

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. The INVOcell system (pictured above) is a novel fertility tre...

Nov 13, 2019 View Article

UnitedHealth Group Appoints Sir Andrew Witty As President

As per reports, Andrew Witty has been appointed as the President for the UnitedHealth Group. Witty is now set to manage enterprise business strategy formulation and development, as president in addition to his responsibilities as Optum CEO. Witty was formerly named as the executive vice president, ...

Nov 13, 2019 View Article

New Commercialization Partners’ Agreements Support INVO Bioscience’s Planned Worldwide Rollout of INVOcell – The World’s Only In Vivo Intravaginal Culture System

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. INVO Bioscience's (IVOB) INVOcell system is a novel fertility treatment tha...

Nov 07, 2019 View Article

“Pause” Vista Partners Daily Market Recap 11/6/19

Wednesday, November 6th seemed to produce a time that most were pausing as the markets were basically flat. The markets' recent runup into record territory called for this to happen and of course, we had to deal with yet another turn of understanding with regard to the trade wars too as stor...

Nov 06, 2019 View Article

Parents Magazine Recognizes INVO Bioscience Pioneers of World’s Only In Vivo Intravaginal Culture System – INVOcell

Parents magazine, a leading publication devoted to parenting from pregnancy to the school years, announced in its recent issue that the Center for Assisted Reproduction in Bedford and Fort Worth, Texas, owned by Drs. Kevin and Kathy Doody have been judged to be one of the 10 Best Fertility Clinics f...

Nov 06, 2019 View Article

“Holy Biotech Batman! (NXTC +248.92%, $2.09B Mkt Cap)” Vista Partners Daily Market Recap 11/5/19

Tuesday, November 5th brought forth a reminder of why I continue to invest in the biotech space as NextCure, Inc. (NXTC) jumped an amazing +248.92% closing at $92.22/share after reaching $109/share. NXTC traded 7.88 million shares and now enjoys a 2.09B market cap. NXTC opened trading at $25.5...

Nov 05, 2019 View Article

“Phase 1 Today” Vista Partners Daily Market Recap 11/4/19

Monday, November 4th brought our attention again towards stories regarding the US-China trade wars. Specifically that we should have confidence that a phase 1 agreement is still on track for this year between these two super economic powers. US Commerce Secretary Wilbur Ross shared that he be...

Nov 04, 2019 View Article

“Smashing” Vista Partners Daily Market Recap 11/1/19

We welcomed our first day of November with the October jobs report surfacing and smashing expectations. The unemployment is now at a 5-decade low while wages were confirmed to have increased a bit. This was indeed enough to give the markets the much-needed fuel to move higher. As a result, th...

Nov 01, 2019 View Article

Pfizer Strong Sales of Cancer Drug Ibrance In Q3 – Raises 2019 Forecast

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

Nov 01, 2019 View Article

“Happy Halloween” Vista Partners Daily Market Recap 10/31/19

Happy Halloween! Well, as the lead picture in this story might indicate it was not so happy of a day for market participants today as the markets sold off for the most part as concerns around the US-China trade wars surfaced its scary head again. Reports that officials in China having doubts...

Oct 31, 2019 View Article

Hits & Misses From Walgreens Q4 Report Plus Jenny Craig Relationship

Walgreen Boots Alliance (WBA), a relatively recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Walgreens Boots Alliance’s reported its fiscal Q4 profit...

Oct 31, 2019 View Article

Please Read Alternative Infertility Treatments Firm INVO Bioscience, Inc.’s (IVOB) New CEO Letter To Shareholders

Today INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of the FDA cleared INVOcell®, the world's only in vivo Intravaginal Culture System, published a letter to shareholders written by its newly ...

Oct 31, 2019 View Article

“Third Time Is A Charm?” Vista Partners Daily Market Recap 10/30/19

It would seem that the Fed's move today to cut interest rates by another quarter-point for the third time this year was indeed a charm as the markets continued moving upward for the most part. The benchmark interest rate is now in a target range of 1.5% to 1.75%. The fed stated that the move w...

Oct 30, 2019 View Article

Merck Records High Q3 Profits, Beat Estimates

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...

Oct 30, 2019 View Article

“Waiting…” Vista Partners Daily Market Recap 10/29/19

As we await the Fed's Wednesday decision to lower interest rates again for the third time this year, the S&P 500 hit an all-time new high prior to ending today's session down by 2.53 points or -.08% as it closed at 3,036.89. Firms making up just over 50% of the S&P 500’s market ...

Oct 29, 2019 View Article

“Looking Probably Ahead” Vista Partners Daily Market Recap 10/28/19

The markets today seemed to be reacting to a number of actions at the macro level that once again buoyed the markets into positive and record territory. Today, according to a Reuters article, one of those factors played a hand we heard from President Trump regarding the US_-China trade wars ...

Oct 28, 2019 View Article

“Positive Sentiment” Vista Partners Daily Market Recap 10/25/19

At the end of the day, the results of the market rose strongly on the sentiment that the US-China trades were heading towards a positive outcome as we head into next week's likely interest rate cut as the Fed makes its decision on Wednesday. The S&P 500 ended today's session up by 12.26 ...

Oct 25, 2019 View Article

Breast Cancer Focused Atossa Genetics Is Presenting At Dawson James Small Cap Growth Conference In Jupiter Oct. 29th

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that Kyle Guse, CFO and General Counsel of Atossa Genetics will be a featured presenter at the 5th...

Oct 24, 2019 View Article

INVO Bioscience Gains EU CE Mark For World’s Only In Vivo Intravaginal Culture System

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the 150 million infertile couples worldwide are treated, or approximately 1.5 million IVF cycles annually, with the primary prohibiting factor being cost and access to treatment. The INVOcell solution, whi...

Oct 24, 2019 View Article

“Microsoft, Dow, Paypal, INVO Bioscience, & Tesla Jump Today” Vista Partners Daily Market Recap 10/24/19

Shares of Microsoft (MSFT), Dow (DOW), Paypal (PYPL), INVO Bioscience (IVOB) & Tesla (TSLA) all jumped today. Microsoft released Q3 earnings after the close yesterday beating expectations as cloud services boosted revenue and ended today's trading at $139.94/share up 1.97%. Dow (DOW) �...

Oct 24, 2019 View Article

“Moderately Green Session” Vista Partners Daily Market Recap 10/23/19

A number of companies from the S&P 500 & Dow 30 continued to report their Q3 earnings again today with varying degrees of success or failures to meet Wall Street's expectations, but at the end of the day, the markets ended in moderately green territory. Of note, Boeing (BA) reported ea...

Oct 23, 2019 View Article

NBA Champion Michael Jordan Funding Healthcare Clinics In Charlotte

Last week, Michael Jordan, a six-time NBA champion and owner of Charlotte Hornets unveiled its first out of two medical clinics in the North Carolina city. The clinics which are strategically placed in areas in need of quality medical care will offer health-care services to Charlotte residents, incl...

Oct 23, 2019 View Article

Positive Topline Results For Seattle Genetics’ Metastatic HER2-Positive Breast Cancer Study

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. An estimated 271,270 new cases of invasive breast cancer will be diagnosed in the U.S. in 2019.1 Between 1...

Oct 23, 2019 View Article

“Earnings & Brexit” Vista Partners Daily Market Recap 10/22/19

A number of companies from the S&P 500 & Dow 30 continued to report their Q3 earnings today while the Brexit reared its ugly head towards the end of the day to put a damper on any excitement that was bubbling early in the markets. Procter & Gamble (PG) beat expectations, United Tec...

Oct 22, 2019 View Article

“Apple Leads Market” Vista Partners Daily Market Recap 10/21/19

Apple (AAPL) hit a new high as Raymond James updated its AAPL price target from $225 to $280 today which in turn led the market forward. AAPL shares closed at $240.51/share after hitting a new all-time high of $240.99 a touch higher. At the end of the day, the S&P 500 ended today's sessio...

Oct 21, 2019 View Article

“Heavy Friday” Vista Partners Daily Market Recap 10/18/19

The market traded in the red today as a few issues were feeling a bit heavy. Johnson & Johnson (JNJ) with the headlines swirling about their baby powder which was apparently found to have traces of asbestos, Boeing (BA) with a report that surfaced suggesting that they may have misled the F...

Oct 18, 2019 View Article

“Splash Of Green” Vista Partners Daily Market Recap 10/17/19

It was a splash of green for all across the board in the markets today as it pointed to a number of better than expected earnings reports and news from across the pond that a Brexit deal may be in the works. The S&P 500 ended today's session up by 8.26 points or .28% as it closed at 2,99...

Oct 17, 2019 View Article

Pfizer Shares Results Of Phase 3 Data For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

Oct 17, 2019 View Article

J&J Exceeds Q3 Expectations/Raises Full-Year Forecasts In the Face Of Legal Issues

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. On Tuesday, Johnson & Johnson reported their successful Q3 earnings, confirming that they had...

Oct 17, 2019 View Article

3M Acquires Acelity, Inc.

Reportedly, 3M (MMM) has completed the acquisition of Acelity, Inc., a leading global medical technology and its worldwide KCI subsidiaries for a total enterprise value of approximately $6.7 billion inclusive of debt and other adjustments. The deal was advised by Apax Partners along with controlled ...

Oct 17, 2019 View Article

UnitedHealth Group (UNH) Releases Its Q3 Analyst Beating Earnings Report

UnitedHealth Group Incorporated (UNH) declared its Q3 earnings report ending Sep 30th, on Tuesday exceeding analysts' expectations and raising its 2019 earnings forecast to 14.90 to $15 per share, in comparison to an earlier forecast of between $14.70 and $14.90, as per reports. UNH's revenues saw ...

Oct 17, 2019 View Article

“Mixed At Best” Vista Partners Daily Market Recap 10/16/19

The S&P 500 ended today's session down by 5.99 points or .2% as it closed at 2,989.69 just shy of the 3k level. The Dow lost 22.82 points closing over the 27k level at 27,001.98 down by .08%. The tech-heavy Nasdaq Composite closed above the 8k mark closing at 8,124.18 down .30% or 24.5...

Oct 16, 2019 View Article

The Dr. Susan Love Research Foundation, A “Major” Research University & Atossa Genetics (ATOS) Are Collaborating On Phase 2 Study of Intraductal Microcatheter Technology In Breast Cancer

The Dr. Susan Love Foundation for Breast Cancer Research's mission is to end breast cancer. It challenges the status quo to end breast cancer and improve the lives of people impacted by it now through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditio...

Oct 16, 2019 View Article

“A Fresh Wave Of Earnings” Vista Partners Daily Market Recap 10/15/19

Today, a wave of earnings kicked into high gear today which seemed to block out the ongoing trials and tribulations of the US-China trade war and we managed to have a very positive day in the markets. From the Dow 30, Johnson & Johnson (JNJ) reported earnings of $2.12, beating estimates of...

Oct 15, 2019 View Article

Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

Steven Quay received an M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over...

Oct 14, 2019 View Article

“Simply Red Columbus” Vista Partners Daily Market Recap 10/14/19

Today felt like a day where many were hiding or trying to hide in the US as schools, banks, and a few other companies celebrated the Columbus Day holiday but there is no rest for the wicked as the markets were open. It was lighter than normal volume day as many did play a bit of hookey and mad...

Oct 14, 2019 View Article

Creator Of Alternative Infertility Treatments INVO Bioscience Hires NEW CEO Steven Shum

Infertility is “the inability to conceive after 12 months.” This means that a couple is not able to become pregnant after a year of trying. However, for women aged 35 and older, the inability to conceive after 6 months is generally considered infertility. According to fertilitycenter.com, the ab...

Oct 14, 2019 View Article

J&J Ordered To Pay Record Amount For Its Antipsychotic Drug Believed To Have Caused Gynecomastia

Reportedly, Johnson & Johnson has been asked to pay $8 billion as penalty charges to Nicholas Murray,who previously won $680,000 over his claims where J&J failed to alert young men over usage of its antipsychotic drug Risperdal causing gynecomastia, growth enlargement of male breasts, in a v...

Oct 14, 2019 View Article

Merck’s Two Applications For DIFICID® Drug On Review Priority List Of FDA

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the le...

Oct 13, 2019 View Article

Walmart Launches Low-Cost Healthcare Program For Its Employees To Curb Its Healthcare Costs

The retail giant, Walmart Stores, Inc. (WMT) with 1.4 million in its collective workforce in the U.S is launching various healthcare pilot programs for its U.S employees starting January 1 in an attempt to cut healthcare costs which are a major expense for the retailer after wages, as per reports. ...

Oct 12, 2019 View Article

“Optimistic Market Music” Vista Partners Daily Market Recap 10/11/19

The optimism and sweet tune or news that the US-China 'partial' trade deal was in play, imminent and apparently agreed to today fueled the market throughout as it reached mid-session highs. The Dow was up over 500 points at one point before tailing off into the close. We should also mention ...

Oct 11, 2019 View Article

“Partial To Green” Vista Partners Daily Market Recap 10/10/19

The US-China trade wars were squarely in the markets' line of view again today. An optimistic understanding flew around the "www" today that at least a partial agreement with China may be in the cards. A meeting with President Trump and China's Vice Premier, Liu He, also had wings and that...

Oct 10, 2019 View Article

Pfizer Presents Interim Analysis From Phase 3 Trial In Advanced BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

Oct 10, 2019 View Article

INVO Bioscience Will Exhibit At The World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26 in Barcelona

Sarasota-based INVO Bioscience, Inc. (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the 20th World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26, 2...

Oct 09, 2019 View Article

“Open…?” Vista Partners Daily Market Recap 10/9/19

All the markets apparently needed today was one word from the Chinese regarding the trade wars, "open", and the game was back on. Mind you that the Chinese only suggested that they were open to a partial deal but again the markets these days seem to hold on to what they want to here and today...

Oct 09, 2019 View Article

“Expanding” Vista Partners Daily Market Recap 10/8/19

"Expanding" seemed to be the word of the day today. First, it was widely reported that the U.S. Commerce Department expanded its Entity List" with 28 additional Chinese firms as they had played some role in "fostering violations of human rights" against a Muslim minority in China. A Beijing f...

Oct 08, 2019 View Article

“Trade, Cut, Confusion” Vista Partners Daily Market Recap 10/7/19

With Warner Brothers' new supervillain movie Joker experiencing an opening weekend with $247M in global ticket sales you might think all is well as headlines flew around the world today preaching its success. However, a Bloomberg article did its best to counter these good feelings with another...

Oct 07, 2019 View Article

“Fragile Wings!” Vista Partners Daily Market Recap 10/4/19

We received a good ending to a volatile week that certainly left many of our heads still spinning. As has been the custom this week the markets seem to be riding up and down on the fragile wings of each piece of economic data more than normal. Today, the economic schedule confirmed that the Se...

Oct 04, 2019 View Article

Walgreen Collaborates With Novant Health To Expand Retail Health Care In North Carolina

Walgreen Boots Alliance (WBA), a relatively recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Reportedly, Walgreens and Novant Health, a leading healthc...

Oct 04, 2019 View Article

“Rate Cut…!” Vista Partners Daily Market Recap 10/3/19

On Thursday, more economic data was released and hit the markets at 7 am pacific. The markets took an initial nosedive prior to recovering into the close after we received the ISM Non-Manufacturing Index report for September which dropped to 52.6% from the 56.4% mark in August. Layering this p...

Oct 03, 2019 View Article

INVO Bioscience Will Exhibit at American Society for Reproductive Medicine (ASRM) 2019 In Philadelphia Oct. 12-16

Sarasota-based INVO Bioscience, Inc. (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress October 12-16, 2019 in Phi...

Oct 02, 2019 View Article

“Double Down?” Vista Partners Daily Market Recap 10/2/19

No sir!... I am not suggesting you double down on the stock market or anything at this point, however, we did double our consecutive down days today as the markets got stung again & proceeded fall significantly across the board once again. The downward move came in reaction to additional...

Oct 02, 2019 View Article

“Manufacturing Woes” Vista Partners Daily Market Recap 10/1/19

Today, the markets suffered through a bit of negative economic news that came out of the manufacturing sector that seemed to surprise and bring forth woes for many on this first day of October. The Institute for Supply Management’s factory index was reported to have slipped to 47.8 in Septem...

Oct 01, 2019 View Article

Breast Cancer Focused Atossa (ATOS) Successfully Meets All Objectives In Phase 1 Study Today

Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have mammographic breast density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effective in...

Sep 30, 2019 View Article

“Q3 Positively Ends” Vista Partners Daily Market Recap 9/30/19

Today, the markets ended Q3 on a positive swing after a US Treasury representative on Saturday followed up by White House trade advisor Peter Navarro essentially refuted Friday's Bloomberg story that stated that the Trump administration is considering limits to US investors' flows into China ...

Sep 30, 2019 View Article

“China Limits” Vista Partners Daily Market Recap 9/27/19

The markets ended the week on a downward slope as we continued to get less than positive news from many fronts spearheaded by the trade wars that continue to bring uncertainty and weigh on the markets this week. Bloomberg ran a story today stating that the Trump administration is considering l...

Sep 27, 2019 View Article

“Adrift” Vista Partners Daily Market Recap 9/26/19

The markets seemed to be without a great deal of conviction and/or just adrift but lower today in a sea of headlines related to trade wars (Huawei again), tariffs, impeachment, whistleblower action more positive economic reports, and historically low jobless claims. The S&P 500 ended today...

Sep 26, 2019 View Article

“New Homes Push” Vista Partners Daily Market Recap 9/25/19

After yesterday's somewhat somber "impeachment inquiry' news we started out a bit sluggish in the markets & understandably so. Then the market was given some notes from President Trump's call with Ukrainian President Zelensky and the trade wars to a bit of back seat to the new home sales r...

Sep 25, 2019 View Article

Merck’s Blockbuster Keytruda Plus Chemotherapy Demonstrates Improvement In Triple-Negative Breast Cancer

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at th...

Sep 25, 2019 View Article

“Somber” Vista Partners Daily Market Recap 9/24/19

It was sobering if not a somber day in the markets and throughout the US as many seemed to focus on the negative and uncertainty rather than what came about that was positive. In the economy, we learned that the Conference Board's Consumer Confidence Index for September dropped to 125.1 which...

Sep 24, 2019 View Article

“Eyes On German PMI” Vista Partners Daily Market Recap 9/23/19

All eyes were on the German PMI situation on Monday as it showed that the German economy, the European union's largest economy, had contracted in September & confirming that the manufacturing and service sectors worsened. September’s IHS Manufacturing PMI for Germany read 41.4, signal...

Sep 23, 2019 View Article

“No To Montana?” Vista Partners Daily Market Recap 9/20/19

Who says no to visiting Montana this time of year? It's so beautiful & peaceful this time of year, correct? Well...the Chinese that's who. The Chinese agricultural delegates, in fact, dared to say "no" to their previous invite and plan to visit Montana-based farms today. The markets took this ...

Sep 20, 2019 View Article

Fate Therapeutics (FATE) Closes Underwritten Public Offering For Proceeds of ~$173.1 million

San Diego-based Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal...

Sep 20, 2019 View Article

“Ho-Hum” Vista Partners Daily Market Recap 9/19/19

After yesterday's "big decision" was revealed where the Fed met again and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%, we experienced a bit of a "ho-hum" sort of day as the markets pretty much stayed in place on relatively low volume. The ...

Sep 19, 2019 View Article

“7-3 Vote” Vista Partners Daily Market Recap 9/18/19

Well, we got it, folks. Yes, the Fed met again today and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%. This move was as the market had widely expected. President Trump also continued to tell the Fed tht they have it all wrong stating "Jay Pow...

Sep 18, 2019 View Article

“Fed Up Next” Vista Partners Daily Market Recap 9/17/19

The broad markets finished higher again today, except for the Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index which moved lower by .40% or 6.31 points closing at 1,578.29. the overall positive move came about with the impending interest...

Sep 17, 2019 View Article

Merck’s Treatment For Rare NSCLC Gains FDA Breakthrough Therapy Designation

Reportedly, Merck KgaA’s tepotinib, a treatment for the MET exon14 skipping mutation in the genetic makeup of a lung tumor, has been awarded the U.S. Food and Drug Administration's breakthrough therapy designation. Breakthrough therapy is a United States Food and Drug Administration designation ...

Sep 12, 2019 View Article

Atossa Genetics Completes Enrollment, Dosing & Expects to Report Preliminary Results For Phase 1 Study Of Oral Endoxifin in Next 30 Days

It is estimated that approximately ten million women in the United States have MBD, for which there is no FDA-approved treatment. Although oral tamoxifen is approved to prevent breast cancer in “high-risk” women, it is used by less than 5 percent of women with an increased risk of developing b...

Sep 03, 2019 View Article

Amgen Gears Up To Own Worldwide Rights Of Otezla®

Reportedly, Amgen (AMGN) has entered in an agreement with Celgene Corporation (CELG) to acquire the worldwide rights of the only oral, a non-biologic treatment for psoriasis and psoriatic arthritis, Otezla. The acquisition is set to proceed for an amount of $13.4 billion in cash, or approximately...

Aug 29, 2019 View Article

Record Q2 Announced By Fertility Med Device Firm INVO Bioscience- (Increase of 498%)

Sarasota, FL-based INVO Bioscience, Inc. (IVOB), a medical device company that was granted FDA clearance for its Intravaginal Culture System, INVOcell®, released its financial results for Q2 2019. The INVO Procedure is a new and effective fertility treatment option allowing fertilization and ear...

Aug 14, 2019 View Article

Seattle’s Atossa Genetics (ATOS) Published Q2 Financial Results & Company Update

Seattle-based Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today published their financial results for Q2, 2019 and provided an update on recent company developments. ...

Aug 13, 2019 View Article

Pfizer Spinning Combined Off-Patent Drug Business With Generic Drugmaker Mylan NV

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer annonced that it will combinen off-Patent Drug Business, Upjohn, with generic drugmaker Mylan NV. This combination will surfacd on the...

Jul 31, 2019 View Article

Atossa Genetics CEO Steven Quay Gives Tedx Talk Regarding Relationship of Dense Breast Tissue & Breast Cancer Risk

Steven Quay is the founder of Seattle-based Atossa Genetics, Inc., dedicated to breast cancer prevention. He received a Ph.D. in Biological Chemistry and a M.D. from the University of Michigan, a postdoc at MIT and Harvard, and he was a faculty member at Stanford Medical School. His contributions ...

Jul 30, 2019 View Article

Walgreen Growing Kaleo Partnership Amid National Shortage Of Allergy Shots

Walgreen Boots Alliance (WBA), a recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Last week, Walgreens Boots Alliance Inc announced that it is ex...

Jul 16, 2019 View Article

J&J Continuing Research For Mid-Stage HIV Vaccine

As per reports, Johnson & Johnson (JNJ) is staged to move forward with a late-stage study of an investigational vaccine for Human Immunodeficiency Virus (HIV), a condition that weakens the immune system of the body in countries like America and Europe. The company is continuing its research...

Jul 14, 2019 View Article

Microsoft Partnering With Providence St. Joseph Health To Move to the Cloud

Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses, supports and sells computer software, consumer electronics, personal computers, and related services. Recently, Providence St. Joseph Health and Microsoft reportedly entered ...

Jul 10, 2019 View Article

MARK THESE DATES ALERT: Biohaven Pharmaceutical Holding Company (BHVN) July 11-14, 2019

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectu...

Jul 09, 2019 View Article

Pfizer Presented Data On Duchenne Muscular Dystrophy (DMD) In Florida

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc introduced the initial Phase 1b clinical data on PF-06939926 at 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference...

Jul 05, 2019 View Article

Atossa Genetics Reports Preliminary Analysis From Phase 2 – “Proprietary Topical Endoxifen Significantly Reduced Breast Density”

Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have Mammographic Breast Density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effect...

Jun 27, 2019 View Article

Pfizer To Acquire Array BioPharma Seeking to Strengthen Its Innovative Biopharmaceutical Business

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. This week, Pfizer Inc announced to acquire Array BioPharma Inc in a definitive merger agreement. Array BioPharma Inc, a biopharmaceutical company ...

Jun 24, 2019 View Article

Low-Cost Fertility Treatment Firm INVO Bioscience Hires Former Cooper Surgical Executive

On a worldwide basis, there are approximately 150 million infertile couples. Approximately 1.5 million IVF cycles are performed annually corresponding to approximately 1% of the infertile couples worldwide. Including IUI (another 1% worldwide), this represents an approximate $6.6 billion worldwi...

Jun 20, 2019 View Article

Antisense Focused Stoke Therapeutics’ IPO Is Off To A Great Start Today!

Bedford, Massachusetts-based Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. They develop antisense oligonucleotide medicines that increase gene expression to treat genetic epile...

Jun 19, 2019 View Article

Exciting FDA Approval Gained For Merck’s Keytruda in Treatment of Head & Neck Cancer

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at th...

Jun 17, 2019 View Article

Merck Announces The Acquisition Of TGFβ Focused Tilos Therapeutics

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be a...

Jun 12, 2019 View Article

INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director Michael Dinkins

One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.06/share & a low of $2.895/share today and closed the day at $2.93/share down 4.56% on...

May 29, 2019 View Article

Oklahoma Attorney General Mike Hunter Files Multibillion-dollar “Opioid” Case Against J&J

Reportedly Johnson & Johnson (JNJ) has been accused of using deceitful methods to encourage the over-use of opioid painkillers that has led to a U.S. opioid epidemic. Mike Hunter, Oklahoma Attorney General recently filed a multi-billion dollar case demanding J&J to pay for helping cau...

May 29, 2019 View Article

Travelers Now Targeting Medical Tech, Pharmaceuticals & Digital Health Firms With Life Sciences Offering

Recently, The Travelers Companies, Inc. (TRV) was reported to have introduced a complete Life Sciences practice offering insurance and risk management solution in pharmaceuticals, digital health and medical devices including health care IT, medical software, and telemedicine. Their program is ...

May 28, 2019 View Article

FDA Approves Novartis AG’s PI3K Inhibitor Treatment For Advanced Breast Cancer In Men & Women

According to multiple reports on Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s PI3K inhibitor treatment, a drug called alpelisib, which will be marketed under the brand name Piqray. Piqray is approved to be administered in combination with hormone therapy for post...

May 25, 2019 View Article

Merck Acquiring Peloton Therapeutics Pushing to Diversify Offerings In Cancer

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at ...

May 23, 2019 View Article

INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director James S. Ely III

One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.29/share & a low of $3.115 today and closed the day at $3.28 up nicely 3.14% on 1.23 m...

May 20, 2019 View Article

Australian Competition and Consumer Commission Pushes Forward GSK-Pfizer Consumer Healthcare Business

The GlaxoSmithKline' deal seeking to purchase & combine Pfizer's consumer healthcare business with their own has recently received approval from Australia’s antitrust regulator recently called the Australian Competition and Consumer Commission (ACCC.) It was reported that the ACCC anti...

May 14, 2019 View Article

Seattle’s Atossa Provides Q1 Results & Progress Developments

Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. On Monday after the market close Atossa announced their financial results for the quarter ended Ma...

May 14, 2019 View Article

UnitedHealth Group Initiates “Low Cost” Maternity Care Programs

Increasing healthcare costs has become a major concern in the United States especially when it comes to maternity costs from prenatal to postpartum care which has been surging. Now UnitedHealth Group Incorporated (UNH) has come up with a health care plan to cut maternity cost where partner hospita...

May 09, 2019 View Article

Pfizer’s Drug For Treating Fatal Heart Disease Gains FDA Approval

Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc.'s oral drug tafamidis effective in treating “transthyretin amyloid cardiomyopathy”, a rare and fatal heart disease recently gained appr...

May 09, 2019 View Article

Hope For Restoring Young Cancer Patient’s Fertility Emerges After New Research

Researchers with the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute, have successfully restored fertility to non-human primate model of childhood cancer, creating hope that the same process may be successful in humans. The researchers were able to cryopreserve ...

May 03, 2019 View Article

United Healthcare Received $4.5M Funded 5-year Accountable Health Communities Award In Hawaii

United Healthcare recently received a $4.5 million funded 5-year Accountable Health Communities award from the Centers for Medicare & Medicaid Services (CMS) to improve social related health services in Oahu, Hawaii. The program seeks to partner with Waianae Coast Comprehensive Health Center, ...

May 02, 2019 View Article

“A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy”

Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced this week that Steven C. Quay, M.D., Ph.D., Atossa’s President, and CEO, provided an update on the Company�...

Apr 26, 2019 View Article

UnitedHealthcare Widens Collaboration With Care Providers In More Than 30 States

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company's UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employ...

Apr 15, 2019 View Article

FDA Approves Johnson & Johnson’s Advanced Bladder Cancer Drug

According to The American Cancer Society’s website estimates for bladder cancer in the United States for 2019 are about 80,470 new cases of bladder cancer (about 61,700 in men and 18,770 in women and about 17,670 deaths from bladder cancer (about 12,870 in men and 4,800 in women. The rates of n...

Apr 15, 2019 View Article

Walgreens & VillageMD Integrating Adult Primary Health Care & Pharmacy Offering In Houston

Leading Primary health care provider VillageMD and Walgreen announced that they are coming together to offer valuable primary health care services under the brand “Village Medical at Walgreens” to adult patients within the Houston community. Initially, VillageMD is to set up health care clin...

Apr 12, 2019 View Article

Breast Cancer Treatment Innovator Atossa Genetics Announced Year End 2018 Financial Results & Provided Business Update This Week

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Today Atossa announced year-end 2018 financial results and provided an update on recent company de...

Mar 28, 2019 View Article

Institutional Review Board Approves Use of Atossa’s Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) ("Atossa") is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Shares of Atossa jumped to a high of $4.865 today and are currently trading at $4.14 u...

Mar 26, 2019 View Article

Breast Cancer Treatment Focused Biotech Atossa Genetics (NASDAQ: ATOS) Raises $10 Million – Jumps Again!

Atossa Genetics (ATOS) a Seattle-based biotech firm focused on developing treatments for breast cancer had another wonderful day as it jumped up 24.47% closing at $4.40 on 24.84 Million shares of trading. This increase came about today as ATOS announced that on March 14th and 15th, 2019, it rece...

Mar 18, 2019 View Article

MARKET ALERT: Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...

Mar 14, 2019 View Article

INVO Bioscience Partners with “Egg Whisperer” To Launch San Francisco Bay Area Embryology Center

MEDFORD, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experi...

Mar 13, 2019 View Article

Developer of Programmed Cellular Immunotherapies Fate Therapeutics (NASDAQ: FATE) Reports Q4 & Full Year 2018 Financial Results – Highlights Operational Progress

San Diego-based Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31...

Mar 05, 2019 View Article

American Society of Breast Surgeons Now Recommends Genetic Testing for All Breast Cancer Patients

The American Society of Breast Surgeons released new recommendations last Thursday that suggested genetic testing for inherited mutations should be offered to all breast cancer patients. These recommendations are in somewhat of opposition with those offered by the National Comprehensive Cancer Ne...

Feb 19, 2019 View Article

MARKET ALERT: Atossa Updates Status of Pre-menopausal, Estrogen-receptor Positive Breast Cancer Patient

Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...

Feb 08, 2019 View Article

Fertility Treatment Innovator INVO Bioscience Adds Michael J. Campbell as COO/VP of Business Development

Medford, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation tha...

Feb 06, 2019 View Article

Breast Cancer Treatment Innovator Atossa Genetics’ CEO Issues Annual Letter to Shareholders Highlighting Strategy for 2019

Seattle-based Atossa Genetics Inc. (ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions issued the following letter from Dr. Steven C. Quay, President, and CEO, to Atossa shareholders: ...

Jan 29, 2019 View Article

INVO Bioscience & Ferring Pharmaceuticals Close Exclusive U.S. Licensing Agreement to Commercialize INVOcell™ For Treatment of Infertility

INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology & is a revolutionary in vivo method of vaginal incubation that offers patients a more natural a...

Jan 28, 2019 View Article

Lilly Paying $8 Billion for Loxo Oncology During JPM2019

JPMorgan Healthcare Conference week brings forth another sizable deal as Lilly (LLY) will commence a tender offer to acquire all outstanding shares of Loxo Oncology (LOXO) for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. Lilly is reported to be making a bet on a ...

Jan 07, 2019 View Article

Largest Pharmaceutical Deal Ever to Take Place Between Bristol-Myers and Celgene

In the biggest pharmaceutical deal ever, Bristol-Myers Squibb will buy Celgene for $74 billion, combining two the largest cancer drug businesses in the world. Wall Street analysts have questioned whether this merge would solve the individual challenges the two companies face. The companies have st...

Jan 07, 2019 View Article